Archive for August, 2016

$NYMX Successful New Long-Term #Fexapotide Placebo Crossover Study Results

HASBROUCK HEIGHTS, N.J., Aug. 24, 2016  — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company’s lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer. The aim of the study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In the new study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients’ discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed. Results have now shown that there was 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).

“These exciting results from this long-term prospective analysis confirm what I and other researchers have consistently seen in the clinic —  that it is obvious that fexapotide greatly helps patients in terms of symptomatic benefit for their BPH;  and with these results, the clinical benefit also results in much less need for surgical intervention over the long-term. I believe these clinical results, combined with previously reported incidence and progression of prostate cancer in this patient population are truly important.  Furthermore, the extreme safety of this new drug and the lack of sexual side effects are remarkably helpful for patients,” said Dr. Mo Bidair, Medical Director of San Diego Clinical Trials in San Diego, CA and an Investigator who has participated for many years in the Fexapotide Clinical Trials.

Nymox has completed and fully financed the execution of seven Phase 3 U.S. BPH (prostate enlargement) clinical protocols, including 2 prospective randomized multicenter single injection double blind clinical trials; 2 U.S. repeat injection clinical trials; and 3 U.S. blinded long-term clinical trial extension studies. In addition, a number of Phase 3 safety and clinical pharmacology studies and analyses have been completed. The Company expects to file for approvals in the next 1-2 quarters.  The Company also expects to report further analyses and results when available in the near future. The Company will publish the findings of the fexapotide clinical trials in peer review medical journals as well as in presentations at medical and urological meetings.

“These prospective study results in blinded placebo crossover patients clearly demonstrate that fexapotide reduces the long-term need for surgery by 82-95% compared to approved conventional BPH treatments”, said Dr. Paul Averback MD, CEO of Nymox. “Fexapotide shows significant efficacy against prostate cancer as a therapeutic, and in addition has been shown to reduce the risk of prostate cancer when fexapotide is used to treat BPH. This is in stark contrast to some conventional BPH treatments in routine clinical use today which on the other hand increase prostate cancer risk, and which have many other well known undesirable side effects,” said Dr. Averback.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2015, and its Quarterly Reports.

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com
Wednesday, August 24th, 2016 Uncategorized Comments Off on $NYMX Successful New Long-Term #Fexapotide Placebo Crossover Study Results

$MKGI Key Milestone – #API and #BookingEngine Complete

Interface to Allow Real-Time Booking Alternative Lodging Inventory Access to Online Travel Agencies (OTA) and Cruise Brokers

WESTON, FL–(Aug 24, 2016) – Monaker Group (OTCQB: MKGI), a technology-driven travel company focused on the alternative lodging rental (ALR) market, announced today that it has completed the design, architecture and buildout of the Monaker Booking Engine (“MBE”) and the Application Program Interface (“API”) is complete.

The completion of the API and corresponding launch of the MBE allows Monaker to work towards partnering with large established Online Travel Agencies, tour operators, airline and cruise originators. Each of these groups will be able to access to Monaker’s alternative lodging, timeshare and resorts inventory, in a Real-Time booking format to which they are accustomed. Monaker’s Booking Engine allows real-time adjustment in inventory, commissions and service fees, which facilitates the ease of use of this platform and interface. This approach and real-time format is believed to be unique to Monaker. Most Alternative Lodging Companies still follow the request/response approach, slowing down the time it takes to receive confirmation.

“The completion of the MBE and API is an important milestone for the Company and our large inventory can now be distributed to our interested partners in the Alternative Lodging industry,” said Bill Kerby, chairman and CEO of Monaker Group. “I’m very pleased with the functionality of the MBE and initial discussions with potential partners has suggested their desire to find a true ‘Plug and Play’ solution. We believe we can now uniquely provide this for the growing travel space. Our goal of becoming one of the larger players in the Alternative Lodging Rental industry can now occur rapidly and we should be adding several large travel industry partners in the near future.”

About Monaker Group

Monaker Group is a technology driven Travel Company with multiple divisions and brands, leveraging more than 60 years of operation in leisure travel. Monaker’s flagship is NextTrip.com, the industry’s first booking engine featuring alternative lodging (vacation home rentals, resort residences and unused timeshares) as well as a vast array of airlines, hotels, cruises, rental cars, tours and concierge services all combined in one platform to give customers the power of choice when booking their vacations. With key partnerships and established travel brands used as cornerstones, the Company’s mission is to continue to expand offerings to become the “one stop” vacation center. Headquartered in South Florida, the Company employs a dedicated team of travel and technology professionals. For more information, visit www.MonakerGroup.com

Safe Harbor Statement:

This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker Group. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, or the expectations of future growth may not be realized. These forward-looking statements are made only as of the date hereof, and Monaker Group, undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker Group’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company’s Annual Report on Form 10-K for the period ended February 29, 2016 which has been filed with the SEC and is available at the SEC’s website at www.sec.gov.

CONTACT:
Monaker Group
Attention: Richard Marshall
Director of Corporate Development
Email: rmarshall@monakergroup.com
Tel: (954) 888-9779

Chesapeake Group
Investor Relations (Monaker)
Tel: (410) 825-3930

Tuesday, August 23rd, 2016 Uncategorized Comments Off on $MKGI Key Milestone – #API and #BookingEngine Complete

$BZUN Launches Warehousing and Logistics Solutions Subsidiary Baotong

SHANGHAI, China, Aug. 23, 2016  — Baozun Inc. (Nasdaq:BZUN) (“Baozun” or the “Company”), the leading brand e-commerce solutions provider in China, today announced the launch of Baotong E-logistics (“Baotong”), a wholly-owned warehousing and logistics solutions subsidiary. Baotong will further strengthen and expand the scale of the Company’s diversified range of warehousing and fulfillment services and improve its ability to serve a larger number of brand partners.

Baotong will serve as a separate logistics entity that will provide warehousing and fulfilment services to brand partners, beginning with the management and operation of Baozun’s seven distribution centers with an aggregate gross floor area of around 180,000 square meters. Final adjustments are currently being made to Baotong’s first premium warehouse, the Baotong Cube, which is expected to officially begin operations in September 2016. The new premium warehouse will be highly automated, significantly improve operational efficiency, provide brand partners with a more customizable solution and support Baozun’s long-term growth by strengthening and expanding the scale of its logistical capabilities.

Baotong will further diversify Baozun’s revenue streams by serving brand partners who are in need of the deep experience in B2C warehousing and fulfillment services. The Company will also be able to provide an enhanced and even more customizable array of logistical services to brand partners across a number of categories as well as improve their operational efficiency. Baotong will directly support the success of brand e-commerce and shape the industry going forward by forming a part of a new generation of intelligent warehousing and fulfillment services.

In addition to the strategic cooperation agreement signed with Alibaba Group Holding Limited’s (“Alibaba”) (NYSE:BABA) logistics arm Cainiao Network Technology Co., Ltd. (“Cainiao”) last year, Baotong will further deepen its relationship with Cainiao by providing best-in-class services to a wider variety of merchants through Cainiao’s platform.

“Creating Baotong as a separate entity is a significant milestone for us in further strengthening our logistical capabilities and another step in providing enhanced warehousing and fulfillment solutions to the e-commerce market as whole,” commented Mr. Vincent Qiu, Chief Executive Officer of Baozun. “As the rapid growth of brand e-commerce continues in China, more and more brands and merchants are seeking experienced and professional B2C warehouse and fulfillment services. By establishing a logistics subsidiary, we will also be able to develop relationships with more brands, starting with logistical services. We are committed to investing in our future as we explore solutions and innovate new services in China’s e-commerce industry.”

Safe Harbor Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

About Baozun Inc.

Baozun is the leading brand e-commerce solutions provider in China that helps brand partners execute their e-commerce strategies. The Company’s integrated capabilities encompass all aspects of the e-commerce value chain, covering IT solutions, store operations, digital marketing, customer services, warehousing and fulfillment. The Company helps brand partners execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations.

For more information, please visit http://ir.baozun.com

For investor and media inquiries, please contact:

Baozun Inc.
Ms. Caroline Dong
ir@baozun.com

Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@ChristensenIR.com
Tuesday, August 23rd, 2016 Uncategorized Comments Off on $BZUN Launches Warehousing and Logistics Solutions Subsidiary Baotong

$APPS & Brightstar To Promote Technology Platforms Globally

Platforms Covered in the Agreement Span Android & iOS Devices To Provide Value-Added Services

AUSTIN, Texas and MIAMI, Aug. 23, 2016  — Digital Turbine, Inc. (Nasdaq: APPS), a global mobile platform company, and Brightstar Corp., a world leader in managing mobile devices across the wireless ecosystem, today announced a global, multi-year agreement  to provide value-added services to carriers and OEMs. Under the terms of the agreement, Brightstar may deploy Digital Turbine’s full suite of technology platforms, including Ignite™, Marketplace™, and Pay™, across targeted market segments. Implementation is expected to begin in the second half of 2016.

“Discovering new ways to enhance customer value is a top priority of ours,” said Nara Kim, Head of Mobile Digital Solutions at Brightstar. “Digital Turbine’s technology platforms enable us to provide more value-added services that create new revenue streams for our mobile operator and OEM partners. Operating at the convergence of mobile and media, we are pleased to work with Digital Turbine at the forefront of mobile monetization solutions.”

“Our end-to-end mobile platforms connect the dots between Operators, OEMs, and Advertisers, enabling monetization across devices and throughout the lifecycle,” said Bill Stone, CEO of Digital Turbine. “We are very excited to partner with Brightstar, an innovative leader with about 200 operator and MVNO partners globally. We offer an efficient way to monetize devices while providing end customers a more engaging user experience. Together with Brightstar, we can bring a new level of targeting capabilities and value added services to mobile operators and OEMs around the world.”

For more information, visit www.digitalturbine.com.

About Brightstar
Brightstar, a subsidiary of SoftBank Group Corp., is a leading provider of B2B services to mobile manufacturers, operators, retailers, and enterprises. With more than 50,000 customers in about 100 countries across six continents, Brightstar is firmly positioned at the center of the wireless ecosystem®. Brightstar touches almost every aspect of a mobile device somewhere in its lifecycle, by providing innovative services that can be seamlessly integrated across customer mobile value chains. Brightstar reported global net revenues of approximately $12.1 billion in 2015. For more information, please visit www.Brightstar.com.

About Digital Turbine
Digital Turbine works at the convergence of media and mobile communications, delivering end-to-end products and solutions for mobile operators, device OEMs, app advertisers and publishers, that enable efficient user acquisition, app management and monetization opportunities. The company’s products include Ignite™, a mobile device management solution with targeted app distribution capabilities, Marketplace™, an application and content store, and Pay™, a content management and mobile payment solution. Digital Turbine Media encompasses a leading independent user acquisition network as well as an advertiser solution for unique and exclusive carrier inventory. Digital Turbine has delivered more than 150 million app installs for hundreds of advertisers. In addition, more than 31 million customers use Digital Turbine’s solutions each month across more than 30 global operators. The company is headquartered in Austin, Texas with global offices in Durham, Berlin, San Francisco, Singapore, Sydney and Tel Aviv. For additional information visit http://www.digitalturbine.com/ or connect with Digital Turbine on Twitter at @DigitalTurbine.

Follow Digital Turbine:

Twitter: https://twitter.com/DigitalTurbine
Facebook: https://www.facebook.com/DigitalTurbineInc
LinkedIn: http://www.linkedin.com/company/digital-turbine

For more information, contact:

Investor relations contact:
Brian Bartholomew
Digital Turbine
ir@digitalturbine.com
(512) 800-0274

Carolyn Capaccio/Sanjay M. Hurry
LHA
(212) 838-3777
digitalturbine@lhai.com

Tuesday, August 23rd, 2016 Uncategorized Comments Off on $APPS & Brightstar To Promote Technology Platforms Globally

$ASTC 1st Detect & Battelle, Awarded #Phase3 of #DOD #ChemicalDetection

– Milestone marks transition from development to prototype

Astrotech Corporation (NASDAQ:ASTC) subsidiary 1st Detect Corporation and strategic partner Battelle Memorial Institute completed the Brassboard Phase and were awarded the Final Prototype Phase of the US military’s Next Generation Chemical Detector (NGCD) Multi-Sample Identifier (MSI) Technology Maturation and Risk Reduction Program. During this upcoming phase, 1st Detect will deliver multiple OEM-1000NG Core Analyzer units for integration into Battelle’s NGCD prototype solution. Battelle is the prime contractor for the Department of Defense’s Joint Program Executive Office for Chemical and Biological Defense (DOD’s JPEO-CBD) next generation chemical detection solution program.

“We are pleased to have passed Phase II,” stated Brent Shroy, Manager of Battelle’s CBRNE Product & Lifecycle Management Business. “1st Detect’s chemical analyzer is the engine that enables the detection of complex compounds with high levels of sensitivity and accuracy. Through our collaboration, we have created a rugged, lightweight instrument that delivers lab quality performance and can be easily employed in the field. We look forward to continuing with 1st Detect to further refine our solution during Phase III.”

“In Phase III, our NGCD solution will undergo additional testing to validate performance in a variety of military operational environments,” stated Thomas B. Pickens III, CEO of Astrotech. “We are confident our collaboration will advance to the EMD phase with the government. Our technical program team has done an outstanding job developing a joint detection solution for use in post-event reconnaissance and surveillance.”

About Battelle Memorial Institute

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.

About 1st Detect Corporation

1st Detect, a subsidiary of Astrotech Corporation (NASDAQ: ASTC), develops, manufactures, and sells powerful, highly sensitive, and accurate mass spectrometers that are used in explosive and chemical warfare detection for the Department of Homeland Security and the military. The 1st Detect technology can also be used in various medical and industrial applications including breath analysis, leak detection and food and beverage manufacturing. These capabilities, combined in an economically priced, transportable, and ruggedized solution, make it an ideal tool for a variety of applications. For more information on 1st Detect Corporation, please visit www.1stDetect.com.

About Astrotech Corporation

Astrotech Corporation (NASDAQ: ASTC) is an innovative science and technology company that invents, acquires, and commercializes technological innovations sourced from research institutions, laboratories, universities, and internally, and then funds, manages, and builds proprietary, scalable start-up companies for profitable divestiture to market leaders to maximize shareholder value. Sourced from Oak Ridge Laboratory’s chemical analyzer research, 1st Detect develops, manufactures, and sells powerful, highly sensitive, and accurate mass spectrometers that can be used in explosive and chemical warfare detection for the Department of Homeland Security and the military. Sourced from decades of image research from the laboratories of IBM and Kodak combined with classified satellite technology from government laboratories, Astral Images sells film to digital image enhancement, defect removal and color correction software, and post processing services providing economically feasible conversion of television and feature 35mm and 16mm films to the new 4K ultra-high definition (UHD), high-dynamic range (HDR) format necessary for the new generation of digital distribution. Sourced from NASA’s extensive microgravity research, Astrogenetix is applying a fast-track on-orbit discovery platform using the International Space Station to develop vaccines and other therapeutics. Demonstrating its entrepreneurial strategy, Astrotech management sold its state-of-the-art satellite servicing operations to Lockheed Martin in August 2014. Astrotech has operations throughout Texas and is headquartered in Austin. For information, please visit www.astrotechcorp.com.

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, whether we can successfully develop our proprietary technologies and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

 

Company Contact:
Astrotech Corporation
Raj Mellacheruvu, 512-485-9530
Chief Operating Officer
IR Contact:
LHA Investor Relations
Cathy Mattison and Kirsten Chapman, 415-433-3777
ir@astrotechcorp.com

Tuesday, August 23rd, 2016 Uncategorized Comments Off on $ASTC 1st Detect & Battelle, Awarded #Phase3 of #DOD #ChemicalDetection

$URRE New Energy Metals Business #Acquires Its First #Lithium Property in #Nevada

CENTENNIAL, Colo., Aug. 23, 2016  — Uranium Resources, Inc. (URI)  (Nasdaq:URRE) (ASX:URI), announced today that it has staked approximately 4,600 acres (1,860 hectares) of placer mining claims covering a prospective target for lithium-enriched brines in the Columbus Salt Marsh area of west-central Nevada. The target area, known as the Nina Project, is situated within a region of known lithium mineralization and is approximately 27 miles (43 kilometers) northwest of the Clayton Valley/Silver Peak lithium brine mine of Albemarle Corporation, the only operating lithium brine recovery operation in the United States.

The acquisition of the Nina Project signals URI’s intent to expand and broaden our corporate efforts into other energy metal commodities, synergistic with the Company’s existing business operations and technical capabilities, in order to create increased shareholder value through exposure to rapidly expanding global energy demand.  URI has advanced its internal program of target identification, exploration and evaluation rapidly, and is now actively acquiring lithium prospects to build a robust and prospective lithium project portfolio.

About the Nina Project:

The Nina Project is located approximately 45 miles (72 kilometers) west of Tonopah, Nevada, is bordered by US highways 6 and 95, and is located near electrical power. The target was initially identified by Company staff through literature reviews of historical geological and geochemical data from the US Geological Survey as well as other information sources, followed by field reconnaissance of the target area. Geochemical sampling returned lithium assay values from near-surface brines that ranged up to 70 and 124 parts per million (ppm) lithium, as determined by the Company’s Kingsville, Texas analytical laboratory and by ALS Minerals in Reno, Nevada, USA. Sediment samples collected from the target area ranged from 98 to 176 ppm lithium as determined through geochemical analyses carried out by ALS Minerals. These assay results generally confirm several of the lithium values from samples collected by the US Geological Survey in 1976, and indicate the target area warrants additional investigation to further characterize the subsurface environment.

The Columbus Salt Marsh, site of the Nina project, is a closed drainage basin covering an area of approximately 370 square miles (960 square kilometers) and whose geology is dominated by lake and evaporite sediments that have been sources of borate, potash and salt in the past.

Near term investigations at the Nina Project will focus on the chemical characterization of the lithium bearing brine aquifers, as well as the vertical and lateral extent of lithium-bearing brines.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/60fd7521-68d1-43f7-84c6-c01d24c0349c

The nearby Clayton Valley (27 miles southeast) is the site of Albemarle Corporation’s Silver Peak lithium-brine mine; the only lithium brine production facility in the United States, which produces approximately 6,000 tonnes of lithium carbonate annually.  The Columbus Salt Marsh is geologically similar to the Clayton Valley, and provides URI with a cornerstone project from which a complete lithium resource portfolio can be built.

About the Lithium Market

Lithium is a critical component for the manufacture of batteries for electrical storage and used in a wide range of devices ranging from cell phones to automobiles.  The battery market is expected to grow 500% over the next 10 years, with lithium batteries accounting for 35% of this growth. At the same time, the transportation sub-market alone is expected to experience a 23% compounded annual growth rate during this same period.

With large battery plants such as Tesla’s “Gigafactory” near Reno, Nevada and Faraday Motor Works’ proposed facility near Las Vegas, Nevada – URI’s Nina Project is at the epicenter of lithium brine development, production and consumption in the United States.

Lithium enriched brines are proven to be less expensive to explore for, develop and operate than other sources of lithium, such as lithium rich pegmatites and hectorite clays.  This advantage of brines is coupled with a small environmental footprint and minimal carbon emissions, which makes ISR mining of brines an attractive method for producing lithium.

For more on the Lithium Market please go to a new page on the Company’s website at www.uraniumresources.com.

Taking advantage of URI’s Expertise

With nearly forty years of corporate experience in the development, operation and restoration of ISR uranium recovery operations, URI is uniquely qualified to expand its business ventures into the lithium brine business. URI is positioned to take advantage of its extensive expertise in:

  • Design, construction, and operation of well fields;
  • The extraction and recovery (hydrometallurgy) of metals from groundwater;
  • Exploration of mineral properties; and
  • Permitting of new projects on privately-owned properties and lands administered by the US Bureau of Land Management and the US Forest Service.

The URI team has successfully explored for a wide range of mineral commodities, from industrial and agricultural minerals, precious metals, uranium and, now, lithium, in the United States and throughout the world. Using a disciplined approach, URI has centered its geological focus to locales, like the Columbus Salt Marsh, that fit a preferred geologic criteria and have the potential to host economic resources of lithium.  Furthermore, the Company’s decades of wellfield design, management, and hydrometallurgical operations experience is directly transferrable to lithium brine extraction and processing. In addition, the Company’s existing facilities also present value in a diversification into lithium, as demonstrated in the use of the existing in-house analytical laboratory at the Kingsville Dome Mine to provide rapid analysis of brine screening samples collected as part of ongoing exploration and evaluation activities.

Christopher M. Jones, President and Chief Executive Officer, said, “Expanding our business into lithium brine exploration and development is a logical next step for URI and capitalizes on our wide range of experience. Diversifying our mineral portfolio while maintaining our uranium business portfolio in readiness for the predicted price rise allows investors increased exposure to the energy industry. We are excited about this new chapter for URI.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Uranium Resources (URI)

URI is focused on developing energy-related metals. In addition to the Nina Project, URI remains focused on advancing the Temrezli in-situ recovery (ISR) uranium project in Central Turkey. URI controls extensive exploration properties under nine exploration and operating licenses covering approximately 32,000 acres (over 13,000 ha) with numerous exploration targets, including the potential satellite Sefaatli Project, which is 30 miles (48 km) southwest of the Temrezli Project. In Texas, the Company has two licensed and currently idled processing facilities and approximately 11,000 acres (4,400 ha) of prospective ISR uranium projects. In New Mexico, the Company controls mineral rights encompassing approximately 190,000 acres (76,900 ha) in the prolific Grants Mineral Belt, which is one of the largest concentrations of sandstone-hosted uranium deposits in the world. Incorporated in 1977, URI also owns an extensive uranium information database of historic drill hole logs, assay certificates, maps and technical reports for the Western United States.

Cautionary Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “anticipates,” “believes,” “could,” and other similar words. All statements addressing events or developments that the Company expects or anticipates will occur in the future, including but not limited to statements relating to mineralization and other developments at the Company’s lithium and uranium projects, synergies between the Company’s uranium and lithium businesses, and future prices and demand for lithium and uranium are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties.  These risk factors and uncertainties include, but are not limited to, (a) the Company’s ability to raise additional capital in the future; (b) spot price and long-term contract price of uranium and lithium; (c) risks associated with our foreign operations; (d) risks associated with the Company expanding its business into lithium; (e) competition from more experienced or better capitalized companies (f) operating conditions at the Company’s projects; (g) government and tribal regulation of the uranium industry and the nuclear power industry; (h) world-wide lithium and uranium supply and demand; (i) maintaining sufficient financial assurance in the form of sufficiently collateralized surety instruments; (j) unanticipated geological, processing, regulatory and legal or other problems the Company may encounter, including in Turkey and in expanding into the lithium business; (k) the ability of the Company to enter into and successfully close acquisitions or other material transactions, including the transaction with Laramide, and other factors which are more fully described in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

Competent Person’s Statement

Technical information in this press release is based on data reviewed by Dean T. Wilton, who is Chief Geologist and Vice President of Uranium Resources, Inc. Mr. Wilton is a “Qualified Person” as defined by Canadian National Instrument 43-101, and a “Competent Person” as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). He is a Certified Professional Geologist (CPG-7659), as designated by the American Institute of Professional Geologists, and is a Member of the Australian Institute of Geoscientists (MAIG #6384). Mr. Wilton has appropriate experience that is relevant to the evaluation of the style of mineral deposits relating to this document. Mr. Wilton consents to the inclusion in this release of the matters based on their information in the form and context in which they appear.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Uranium Resources Contact:
Christopher M. Jones, President and CEO
303.531.0472

Jeff Vigil, CFO and VP Finance
303.531.0473

info@uraniumresources.com
www.uraniumresources.com
Tuesday, August 23rd, 2016 Uncategorized Comments Off on $URRE New Energy Metals Business #Acquires Its First #Lithium Property in #Nevada

$EXPI #FundamentalResearch Corp. Updates Its Coverage of eXp World Holdings, Inc.

Independent Research Firm Raises Fair Value Estimate and Revenue Forecast

BELLINGHAM, WA–(August 23, 2016) – Fundamental Research Corp., an independent research firm specializing in the small-cap and microcap sectors, has announced that it has updated its analysis of eXp World Holdings, Inc. (OTCQB: EXPI). To the view the updated research report in its entirety visit http://www.otcmarkets.com/financialReportViewer?symbol=EXPI&id=159381.

eXp World Holdings, Inc. is the holding company for a number of entities including eXp Realty, the Agent-Owned Cloud Brokerage and First Cloud Mortgage, Inc. The Company’s real estate brokerage operations now has more than 1,600 real estate professionals who span across 41 states, the District of Columbia and parts of Canada.

In the report, Fundamental Research Corp., which initiated coverage of eXp World Holdings, Inc. back in April of this year, cites the Company’s record second quarter revenues and healthy balance sheet and the addition of 2 strong independent board members as well as adding to the company’s Executive team among the reasons for its upward revisions.

All research issued by Fundamental Research Corp. is based on public information. Fees were paid by EXPI to FRC. The purpose of the fee is to subsidize the high costs of research and monitoring. FRC takes steps to ensure independence including setting fees in advance and utilizing analysts who must abide by CFA Institute Code of Ethics and Standards of Professional Conduct. Additionally, analysts may not trade in any security under coverage. Our full editorial control of all research, timing of release of the reports, and release of liability for negative reports are protected contractually. To further ensure independence, EXPI has agreed to a minimum coverage term including four reports.

About eXp World Holdings, Inc.

eXp World Holdings, Inc. is the holding company for a number of companies most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage® as a full-service real estate brokerage providing 24/7 access to collaborative tools, training, and socialization for real estate brokers and agents through its 3-D, fully-immersive, cloud office environment. eXp Realty, LLC and eXp Realty of Canada, Inc. also feature an aggressive revenue sharing program that pays agents a percentage of gross commission income earned by fellow real estate professionals who they attract into the Company.

eXp World Holdings, Inc. also owns 89.4% of First Cloud Mortgage, Inc. a Delaware corporation launched in 2015 and now licensed to originate mortgages in Arizona, California, Virginia and New Mexico. First Cloud Mortgage has positioned itself as a Planet Friendly Mortgage Company via the purchase of carbon offsets for homeowners offsetting the first year of the Carbon Footprint of the typical home on each mortgage originated through First Cloud Mortgage, Inc.

As a publicly-traded company, eXp World Holdings, Inc. uniquely offers professionals within its ranks opportunities to earn equity awards for production and contributions to overall company growth.

For more information you can follow eXp World Holdings, Inc. on Twitter, LinkedIn, Facebook, YouTube, or visit eXpWorldHoldings.com. For eXp Realty please visit: eXpRealty.com and for First Cloud Mortgage, Inc. check out FirstCloudMortgage.com.

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to revise or update them. These statements include, but are not limited to, statements about the Company’s expansion, revenue growth, operating results, financial performance and net income changes. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; and other risks detailed from time to time in the Company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Annual Report on Form 10-K.

Investor Relations Contact Information:
Glenn Sanford
Chairman & CEO
eXp World Holdings, Inc.
glenn@expworldholdings.com
360-389-2426

Contact:
Sid Rajeev, CFA
www.researchfrc.com
Direct: 604-682-7065

Tuesday, August 23rd, 2016 Uncategorized Comments Off on $EXPI #FundamentalResearch Corp. Updates Its Coverage of eXp World Holdings, Inc.

$MOBI Enters into #DefinitiveAgreement for #GoingPrivate Transaction

HANGZHOU, China, Aug. 22, 2016  — Sky-mobi Limited (“Sky-mobi” or the “Company”) (Nasdaq:MOBI), a mobile application platform and game publisher in China, today announced that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Amber Shining Investment Limited (“Parent”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and Power Rich Limited (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly-owned subsidiary of Parent.

Subject to satisfaction of the Merger Agreement’s terms and conditions, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the “Merger”). Pursuant to the Merger Agreement, at the effective time of the Merger, each of the Company’s common shares (including the Company’s common shares in the form of American depositary shares, or “ADSs”, each representing eight common shares) issued and outstanding immediately prior to the effective time of the Merger (the “Shares”) will be cancelled and cease to exist in exchange for the right to receive US$0.275 per Share or US$2.2 per ADS, in each case, in cash and without interest, except for (a) Shares, including such Shares represented by the ADSs, held by Mr. Michael Tao Song, chairman and chief executive officer of Sky-mobi, Xplane Limited and Mobi Joy Limited (collectively, the “Rollover Holders”), Parent (together with the Rollover Holders and the Merger Sub, the “Buyer Group”), the Company or any of their subsidiaries, which will be cancelled and cease to exist and no payment or distribution will be made with respect thereto and (b) Shares held by shareholders who have validly exercised and not effectively withdrawn or lost their rights to dissent from the Merger pursuant to Section 238 of the Companies Law of the Cayman Islands, which will be cancelled and cease to exist in exchange for the right to receive the payment resulting from the procedure set forth in Section 238 of the Companies Law of the Cayman Islands. The consideration of the Merger represents a premium of 25% over the Company’s closing price of US$1.76 per ADS on June 22, 2016, the last trading day prior to the Company’s announcement of its receipt of a “going-private” proposal.

The Buyer Group intends to fund the Merger with the proceeds from a committed loan facility in the amount of US$40 million arranged by China Merchants Bank Co., Ltd., New York Branch, pursuant to a debt commitment letter dated as of today.

The Company’s board of directors (the “Board”), acting upon the unanimous recommendation of a special committee of disinterested directors that are unaffiliated with Parent or Merger Sub (and that are not members of the Company’s management) (the “Special Committee”), authorized and approved the Merger Agreement and the Merger and resolved to recommend that the Company’s shareholders vote to authorize and approve the Merger Agreement and the Merger. The Special Committee negotiated the terms of the Merger Agreement with the assistance of its independent financial and legal advisors.

The consummation of the Merger is subject to customary closing conditions, including the approval of the Merger Agreement by an affirmative vote of holders of at least two-thirds of the Shares present and voting in person or by proxy at a meeting of the Company’s shareholders which will be convened to consider the approval of the Merger Agreement and the Merger. The Rollover Holders have entered into a support agreement pursuant to which each has agreed, among other things, to vote all of his or its Shares in favor of the authorization and approval of the Merger Agreement and the Merger. If completed, the Merger will result in the Company becoming a privately-held company and its ADSs will no longer be listed on the NASDAQ Global Market.

In connection with the Merger, Roth Capital Partners, LLC is serving as a financial advisor to the Special Committee; Orrick, Herrington & Sutcliffe LLP is serving as U.S. legal advisor to the Special Committee; Conyers Dill & Pearman is serving as Cayman Islands legal advisor to the Special Committee; and Cleary Gottlieb Steen & Hamilton LLP is serving as U.S. legal advisor to the Company.

Gibson, Dunn & Crutcher LLP is serving as U.S. legal advisor to the Buyer Group; and Walkers is serving as Cayman Islands legal advisor to the Buyer Group.

Additional Information about the Transaction

The Company will furnish to the U.S. Securities and Exchange Commission (the “SEC”) a report on Form 6-K regarding the Merger, which will include the Merger Agreement. All parties desiring details regarding the Merger are urged to review these documents, which will be available at the SEC’s website (http://www.sec.gov).

In connection with the Merger, the Company will prepare and mail a proxy statement to its shareholders. In addition, certain participants in the Merger will prepare and mail to the Company’s shareholders a Schedule 13E-3 transaction statement. These documents will be filed with or furnished to the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE MERGER AND RELATED MATTERS. In addition to receiving the proxy statement and Schedule 13E-3 transaction statement by mail, shareholders also will be able to obtain these documents, as well as other filings containing information about the Company, the Merger and related matters, without charge, from the SEC’s website (http://www.sec.gov) or at the SEC’s public reference room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. In addition, shareholders will also be able to obtain these documents, without charge, by contacting the Company at the following address and/or telephone number:

Sky-mobi Limited

10/F, Building B, United Mansion

No. 2 Zijinghua Road, Hangzhou

Zhejiang 310013

People’s Republic of China

Telephone: +86-571-87966755

The Company and certain of its directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the Company’s shareholders with respect to the Merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies will be set forth in the proxy statement and Schedule 13E-3 transaction statement relating to the Merger when it is filed with the SEC. Additional information regarding the interests of such potential participants will be included in the proxy statement and Schedule 13E-3 transaction statement and the other relevant documents filed with the SEC when they become available.

This announcement is neither a solicitation of a proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the Merger go forward.

About Sky-mobi Limited

Sky-mobi Limited is a mobile application platform and game publisher in China. The Company works with handset companies to pre-install its Maopao App Store and other Maopao applications on handsets and with content providers to provide users with applications and content titles. Users of Maopao App Store can browse, download and enjoy a range of applications and content, such as single-player games, mobile music and books on various mobile handsets with different hardware and operating system configurations. The Company also publishes domestic and foreign game titles through its own Maopao App Store platform and third party platforms. The Company’s mobile social network community in China, the Maopao Community, offers mobile social games as well as applications and content with social networking functions to its registered users. The Company is based in Hangzhou, China. For more information, please visit: www.sky-mobi.com.

Safe Harbor Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as “may,” “will,” “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “continues” or other similar expressions, the negative of these terms, or other comparable terminology. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company and its industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

For further information, please contact:
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E-mail: lbergkamp@christensenir.com
Monday, August 22nd, 2016 Uncategorized Comments Off on $MOBI Enters into #DefinitiveAgreement for #GoingPrivate Transaction

$LMFA to Present at 5th Annual #LioliosGateway Conference

TAMPA, Fla., Aug. 22, 2016  — LM Funding America, Inc. (NASDAQ:LMFA) (NASDAQ:LMFAW), a specialty finance company offering unique funding solutions to community associations, has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.

LM Funding CEO Bruce Rodgers is scheduled to present on Thursday, Sep 8 at 10:30 a.m. Pacific time, with one-on-one meetings held throughout the day.

The presentation will be webcast live and available for replay on the Investor Relations section of the company’s website at www.lmfunding.com and the Gateway Conference website at www.gateway-conference.com/presenters.

LM Funding provides condominium and homeowner associations (COAs and HOAs) funding solutions to cover delinquent association dues. Management will discuss their recent operational development and financial results.

The Gateway Conference will feature 100 companies in the small/micro-cap space and will be attended by investors, analysts and other influential members of the investment community.

For more information on LM Funding or to request an 1×1 meeting or invitation to the event, please contact Michael Koehler at michael@liolios.com. Please visit www.gateway-conference.com for more information.

About the Gateway Conference

The 5th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.

About LM Funding America

LM Funding America, Inc., together with its subsidiaries, is a specialty finance company that provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado and Illinois. The company offers funding to Associations by purchasing a certain portion of the Associations’ rights to delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It is also involved in the business of purchasing delinquent accounts on various terms tailored to suit each Association’s financial needs, including under its New Neighbor Guaranty™ program. The company was founded in 2008 and is based in Tampa, Florida. The company’s common shares and warrants trade on the NASDAQ Capital Market under the symbols “LMFA” and “LMFAW”.

 

Company Contact:
Bruce Rodgers
Chairman and CEO
LM Funding America, Inc.
Tel (813) 222-8996
investors@lmfunding.com 

Investor Relations Contact:
Michael Koehler
Liolios Group, Inc.
Tel (949) 574-3860
LMFA@liolios.com
Monday, August 22nd, 2016 Uncategorized Comments Off on $LMFA to Present at 5th Annual #LioliosGateway Conference

$MBRX Appoints New #CFO

Seasoned Financial Executive Jonathan P. Foster Joins Moleculin Biotech

HOUSTON, TX–(August 22, 2016) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the appointment of Jonathan P. Foster as Executive Vice President and Chief Financial Officer. Effective today, Mr. Foster will assume the duties of Moleculin’s CFO, Louis Ploth, Jr., who came out of retirement in 2015 to guide the new company through its Initial Public Offering. Mr. Ploth will assist the company with the transition, acting as an independent advisor.

Mr. Foster joins Moleculin from InfuSystem Holdings, Inc., an NYSE MKT listed company and a leading national provider of infusion pumps and related services to the healthcare industry in the United States and Canada, primarily related to the treatment of cancer, where he served as Executive Vice President and Chief Financial Officer, since 2012. He brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies.

Walter Klemp, Chairman and Acting CEO of Moleculin stated, “We are very pleased to announce that Jon Foster has agreed to serve as CFO as we continue to attract seasoned executives with successful track records to our growing company. Having worked alongside Jon in a previous public company setting, I have respect, admiration and the utmost confidence in Jon’s ability to hit the ground running with our highly effective team. His extensive experience in finance, cash management, treasury and information technology will greatly benefit our future. At the same time, we are extremely grateful to Louis Ploth who directed Moleculin through our highly successful Initial Public Offering and listing on NASDAQ.”

During his career, Mr. Foster has raised close to a half billion dollars in public, private and debt financing for companies and reversed financial inefficiencies while accelerating growth to deliver millions of dollars in EBITDA.

At InfuSystem Holdings, Inc., Mr. Foster joined in early 2012 during an Activist takeover and served through multiple subsequent Board and CEO transitions. While working in a close team environment, Mr. Foster led the implementation of accounting, budgeting, corrections of material weaknesses, improvements in internal control and cash control discipline, investigations of strategic alternatives and execution on multiple refinancings. Such actions resulted in revenue growth and a return to profitability. From March 2012 to March 2016, InfuSystem lowered its effective interest rate on its debt from over 18% to under 3% and increased its Enterprise Value by over 50%.

Prior to InfuSystem, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG and the world’s largest provider of airline catering and in-flight services. Prior to that, from 2000-2012, he was President, CFO and majority owner of United Credit, Inc. & Advance Today, Inc., a privately owned consumer finance company with multiple locations. During his time there, Mr. Foster successfully doubled revenue, tripled the firm’s loan base and strengthened business operations and profitability.

From 1996-2000, Mr. Foster served as Executive Vice President and Chief Financial Officer of Drypers Corporation, a publicly traded global consumer products company with more than 2,000 employees internationally and $460 million in revenue, where he worked alongside Moleculin’s Chairman and Acting CEO, Walter Klemp.

He previously served as Chief Financial Officer of Dickson Weatherproof Nail Company, Controller & Treasurer of divisions of Schlumberger Industries, and as a Manager in the Middle Market Group of Deloitte & Touche. He has also served on the State of South Carolina Board of Financial Institutions and the Board of Directors for the Easley Baptist Hospital Foundation.

Mr. Foster has a BS in Accounting from Clemson University, is a Certified Public Accountant and AICPA Chartered Global Management Accountant.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. The other portfolio targets the metabolism of tumors.

For more information about Moleculin, please visit http://www.moleculin.com

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential for future benefit resulting from the experience of our new CFO. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading “Risk Factors” in our Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission on February 1, 2016, as amended (Registration No. 333-209323). Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts
PCG Advisory Group
Kirin M. Smith
Chief Operating Officer
D: 646.863.6519
E: ksmith@pcgadvisory.com

Monday, August 22nd, 2016 Uncategorized Comments Off on $MBRX Appoints New #CFO

$MBVX Announces #Closing of its #PublicOffering

SAN DIEGO, Aug. 22, 2016  — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company announces the closing of its public offering of common stock and Series F Preferred Stock and warrants for a total of $9.4 million, including approximately $800,000 received from the underwriter in exercising the full amount of its over-allotment option.  Sold in the offering were a combination of common stock and Series F Preferred Stock at $4.81 per share of common stock or Series F Preferred Stock, and included one Class A warrant exercisable at $5.55 per share and one Class B warrant exercisable at $6.29 per share for each share of common stock or Series F Preferred Stock sold in the offering.  Both OPKO Health, Inc. (Nasdaq: OPK) and Dr. Phillip Frost, CEO and Chairman of OPKO Health, participated in the offering.

The total gross proceeds of the public offering were before the underwriter’s discount and expenses.  The warrants are immediately exercisable and expire August 17, 2019.  Neither the warrants nor the Series F Preferred Stock will be separately listed on any securities exchange or other trading market.  Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for this offering including exercise of the over-allotment option.

A registration statement relating to these securities was previously filed on Form S-1 (333-211421) with the Securities and Exchange Commission (the “SEC”), and was declared effective by the SEC on August 16, 2016. A final prospectus relating to the offering may be obtained on the SEC’s website located at www.sec.gov, and electronic copies of the final prospectus may also be obtained from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, New York, NY 10036, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines.  MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK.  In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.  MabVax’s two lead antibody clinical programs, currently in Phase I clinical trials, utilize HuMab-5B1 as a naked antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163).  MabVax also has the exclusive license to the therapeutic vaccines from MSK.  Additional information is available at www.mabvax.com.

Forward Looking Statements:

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Contact:
MabVax Investor Relations
858-259-9405 x 302

Monday, August 22nd, 2016 Uncategorized Comments Off on $MBVX Announces #Closing of its #PublicOffering

$LTRX Launches New Premier #Partner #Program for #ITM Resellers

Lantronix SmartAdvantage Program Gives Qualified Resellers Substantial Discounts, Incentives and Tools for Selling Lantronix IT Management Solutions

IRVINE, CA–(Aug 22, 2016) – Lantronix, Inc. (the “Company”) (NASDAQ: LTRX) a specialized networking company providing smart IoT and M2M solutions, today announced the launch of a new premier partner program, Lantronix SmartAdvantage. The program provides substantial discounts, incentives and tools to resellers and VARS when they register a qualified deal for the Lantronix® SLC™ 8000 or other Lantronix IT management solutions.

“The launch of the Lantronix SmartAdvantage program will allow us to aggressively expand access to our industry-leading SLC 8000 solution in the marketplace,” said Jeff Benck, president and CEO of Lantronix. “Our SLC 8000 advanced console manager is hands down the best modular console manager for environments where the need for advanced out-of-band-management and the ability to adapt to changing infrastructure requirements (like USB) are key. With this program, resellers have the opportunity to make more money by providing their customers with innovative Lantronix IT management solutions.”

“Lantronix has been known as a leading provider of robust, easy-to-deploy, secure IT management solutions for more than 20 years,” said Glenn Ramos, vice president of sales and marketing for MicroPac Technologies. “With the launch of this new program, they are once again demonstrating why they are the solution provider of choice for resellers worldwide.”

Interested resellers can register and get more information about the program by going to https://www.lantronix.com/partners or by emailing partners@lantronix.com.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a specialized networking company providing M2M (machine to machine) and IoT (Internet of Things) solutions. Our products deliver secure connectivity, device management and mobility for today’s increasingly connected world. By networking and managing devices and machines that have never before been connected, we enable our customers to realize the possibilities of the Internet of Things. Founded in 1989, Lantronix pioneers robust, intelligent and easy to deploy solutions for mission critical applications in a wide range of industries, including data center, medical, security, industrial, transportation, retail, financial and government. Lantronix is headquartered in Irvine, California, with offices in Europe and Asia. For more information, visit www.lantronix.com.

Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

© 2016 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark, and SLC is a trademark, of Lantronix, Inc. All other trademarks and trade names are the property of their respective holders.

Media:

E.E. Wang
Director, Corporate Marketing and Investor Relations
ee.wang@lantronix.com
949-614-5879

Channel:
Steve Ashauer
Worldwide Channel Manager
sashauer@lantronix.com
949-453-3990

Monday, August 22nd, 2016 Uncategorized Comments Off on $LTRX Launches New Premier #Partner #Program for #ITM Resellers

$SYMX Announces #Restructuring of #ZaoZhuangNewGas

SES and Partner, Shandong Weijiao Group Xuecheng Energy Co., Ltd., to Evaluate New ZZ Facility in Zouwu Industrial Park

HOUSTON, Aug. 19, 2016  — Synthesis Energy Systems, Inc. (SES) (NASDAQ:SYMX), the global leader of full-range feedstock flexibility in advanced energy gasification technology, announced that the Company, and its JV partner, Shandong Weijiao Group Xuecheng Energy Co., Ltd. (Xuecheng Energy), have entered into a Definitive Agreement to restructure the Zao Zhuang New Gas Company Joint Venture (ZZ). Additionally, to dovetail with the Chinese government’s widespread initiative to move industry into larger scale, commercial and environmentally beneficial industrial parks, the partners intend to evaluate a new ZZ syngas facility in the Zouwu Industrial Park in Shandong Province. SES will retain an approximate nine percent ownership in the ZZ JV asset, and Xuecheng Energy has agreed to assume all outstanding liabilities of the ZZ JV. The agreement will take effect formally when the registration with the government is completed, which is expected within 30 days.

The ZZ facility, SES’s proof-of-concept plant and feedstock test facility with two SGT systems in Zao Zhuang City, Shandong Province, first produced clean syngas in December 2007. With the Chinese government’s widespread initiative to move heavy industry into larger scale industrial parks outside the city, the coke ovens owned by Xuecheng Energy which had produced coke oven gas for the ZZ JV, ceased operation in October 2015. SES has evaluated numerous options to repurpose the ZZ facility. It was determined that due to the same industrial park initiative, repurposing at the current site would not be an option. Xuecheng Energy has since constructed and is currently operating new and larger coke ovens, as well as an LNG manufacturing facility, at the Zouwu Industrial Park.

To further improve the effectiveness of its new facility, Xuecheng Energy is evaluating plans to build a project to upgrade the operation’s coal tar by-product to produce more valuable products including fuels, and has received the local government approval for the project. Additional syngas will be required for this operation, which is intended to be produced in the new industrial park via the restructured ZZ JV. Further, Rui Feng Enterprises is also making plans to proceed with its acetic anhydride facility at the new site. SES has retained a right to invest in the new ZZ project and Xuecheng Energy has agreed to utilize SGT for the syngas production there.

“This was a long thought through, tough decision to restructure ownership and start fresh, but one we believe is the right one to bring value – and a future – to the ZZ asset,” said DeLome Fair, SES President and CEO. “We plan to carefully evaluate the new opportunity for SES to join with Xuecheng Energy through investment into these new industrial park projects which rely on syngas from our SGT technology and which over time may serve additional multi-use needs as the industrial park expands.”

If the project moves forward, the new ZZ facility in the Zouwu Industrial Park will be the third industrial park planned to house SGT systems in Shandong Province. The other two, announced in Spring 2016, are Lijin County Binhai New District and Hekou Blue Economy Industrial Park Project, both in Dongying City.

About Synthesis Energy Systems, Inc.

Synthesis Energy Systems (SES) is a Houston-based technology company focused on bringing clean high-value energy to developing countries from low-cost and low-grade coal, biomass and municipal solid waste through its proprietary gasification technology based upon U-Gas®, licensed from the Gas Technology Institute. The SES Gasification Technology (SGT) can produce clean, low-cost syngas for power generation, industrial fuel gas, chemicals and transportation fuels, replacing expensive natural gas based energy. SGT enables Growth With Blue Skies, and greater fuel flexibility for both large-scale and efficient small- to medium-scale operations close to fuel sources. Fuel sources include low-rank, low-cost high ash, high moisture coals, which are significantly cheaper than higher grade coals, many coal waste products, biomass, and municipal solid waste feedstocks. For more information, please visit: www.synthesisenergy.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the ability of our project with Yima to produce earnings and pay dividends; our ability to develop and expand business of the TSEC joint venture in the joint venture territory; our ability to successfully partner our technology business; our ability to develop our power business unit and marketing arrangement with GE and our other business verticals, including DRI steel, through our marketing arrangement with Midrex Technologies, and renewables; our ability to successfully develop the SES licensing business; the ability of the ZZ Joint Venture to repurpose its existing facility or  develop a new SGT facility using its existing systems; events or circumstances which result in an impairment of our assets; our ability to reduce operating costs; our ability to make distributions and repatriate earnings from our Chinese operations; our limited history, and viability of our technology; commodity prices, including in particular methanol, and the availability and terms of financing; our ability to obtain the necessary approvals and permits for future projects; our ability to raise additional capital, if any, and our ability to estimate the sufficiency of existing capital resources; the sufficiency of internal controls and procedures; and our results of operations in countries outside of the U.S., where we are continuing to pursue and develop projects. Although SES believes that in making such forward-looking statements our expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected by us. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Contact:

MDC Group
Investor Relations:
David Castaneda
Arsen Mugurdumov
414.351.9758
IR@synthesisenergy.com

Media Relations:
Susan Roush
805.624.7624
PR@synthesisenergy.com

Friday, August 19th, 2016 Uncategorized Comments Off on $SYMX Announces #Restructuring of #ZaoZhuangNewGas

$PLUS Announces #Stock #RepurchaseProgram

HERNDON, Va., Aug. 19, 2016  — ePlus inc. (NASDAQ:PLUS) today announced that its board of directors has authorized the Company to repurchase up to 500,000 shares of ePlus’ outstanding common stock over a 12-month period commencing August 19, 2016.  The Company’s former repurchase plan expired August 16, 2016.  ePlus had approximately 7.1 million shares of common stock outstanding as of July 29, 2016.

The purchases may be made from time to time in the open market, or in privately negotiated transactions, subject to availability.  Any repurchased shares will have the status of treasury shares and may be used, if and when needed, for general corporate purposes.  ePlus has no obligation to repurchase shares under the authorization, and the timing, actual number and value of the shares which are repurchased will be at the discretion of management and will depend on a number of factors, including the price of the Company’s common stock. The Company may suspend or discontinue repurchases at any time.

About ePlus inc.

ePlus is an engineering-centric technology solutions provider that helps organizations imagine, implement, and achieve more from their technology.  With the highest certifications from top technology partners and expertise in key technologies from data center to security, cloud, and collaboration, ePlus transforms IT from a cost center to a business enabler.  Founded in 1990, ePlus has more than 1,000 associates serving a diverse set of customers nationally, and in Europe.  The Company is headquartered at 13595 Dulles Technology Drive, Herndon, VA, 20171.  For more information, visit www.eplus.com, call 888-482-1122, or email info@eplus.com.  Connect with ePlus on Facebook at www.facebook.com/ePlusinc and on Twitter at www.twitter.com/ePlus.  ePlus. Where Technology Means More®.

ePlus®, Where Technology Means More®, and ePlus products referenced herein are either registered trademarks or trademarks of ePlus inc. in the United States and/or other countries.  The names of other companies, products, and services mentioned herein may be the trademarks of their respective owners.

Statements in this press release that are not historical facts may be deemed to be “forward-looking statements.”  Actual and anticipated future results may vary materially due to certain risks and uncertainties, including, without limitation, possible adverse effects resulting from financial market disruption and general slowdown of the U.S. economy such as our current and potential customers delaying or reducing technology purchases, increasing credit risk associated with our customers and vendors, reduction of vendor incentive programs, and restrictions on our access to capital necessary to fund our operations; our ability to consummate and integrate acquisitions; the possibility of goodwill impairment charges in the future; significant adverse changes in, reductions in, or losses of relationships with major customers or vendors; the demand for and acceptance of, our products and services; our ability to adapt our services to meet changes in market developments; our ability to implement comprehensive plans for the integration of sales forces, cost containment, asset rationalization, systems integration and other key strategies; our ability to reserve adequately for credit losses; our ability to secure our electronic and other confidential information; future growth rates in our core businesses; the impact of competition in our markets; the possibility of defects in our products or catalog content data; our ability to adapt to changes in the IT industry and/or rapid change in product standards; our ability to realize our investment in leased equipment; our ability to hire and retain sufficient qualified personnel; and other risks or uncertainties detailed in our reports filed with the Securities and Exchange Commission.  All information set forth in this press release is current as of the date of this release and ePlus undertakes no duty or obligation to update this information.

Contact: 
Kleyton Parkhurst, SVP
ePlus inc.
kparkhurst@eplus.com
703-984-8150
Friday, August 19th, 2016 Uncategorized Comments Off on $PLUS Announces #Stock #RepurchaseProgram

$CALL #magicJack for BUSINESS Opens Corporate HQ in #Atlanta Area

WEST PALM BEACH, Fla. and NETANYA, Israel, Aug. 19, 2016  — magicJack for BUSINESS, a division of leading cloud-based communications company, magicJack VocalTec, Ltd. (Nasdaq:CALL), created to deliver easy-to-use, highly reliable and cost effective Internet phone systems to small businesses, announced today the opening of its corporate headquarters in Alpharetta, Georgia. Located in the Northwinds planned development, the company will occupy the fourth floor of the Northwinds IV building, with plans to grow its team and hire up to 150 employees by the end of 2017.

magicJack for BUSINESS was launched by magicJack VocalTec, a pioneer in Voice over IP (VoIP) technology and services with a revenue of over $100M in 2015. Building off of magicJack’s success in the consumer market, magicJack for BUSINESS was created as a wholly owned subsidiary to meet the unique needs of small–to-medium sized businesses (SMBs) with an easy-to-use, highly reliable business Internet phone system. Its feature-rich, simplified flat rate offering was created for entrepreneurs and business owners who strive for the most reliable and clearest phone service to keep them professionally connected to their customers, while keeping expenses low.

The company selected Alpharetta for its close-knit business community, growing technology sector, abundance of talent, knowledge and experience, as well as its convenient proximity to Atlanta.  Now home to more than 600 tech-based companies, Alpharetta was recently recognized by Forbes magazine as the number one place to relocate in the U.S., and highlighted in a recent report by NerdWallet and Entrepreneur Media as the best small city in the United States to start a business, based upon business climate, economic health and other factors.

“We are focused on small businesses and are excited to be headquartered in the heart of a community that is technology focused, embraces SMBs and supports our desire to help them grow and prosper,” said Keith Reed, Senior Vice President and General Manager at magicJack for BUSINESS. “We are looking forward to expanding our team with local talent and participating in Alpharetta’s technology circle.”

magicJack for BUSINESS is currently hiring for positions across the company including software development, sales and customer care.

Reed added, “We are staged for growth and bring a positive culture and significant opportunity for success. We believe our business will continue to flourish here by bringing revenue and employment opportunities to the community.”

To apply for open positions, visit the company’s LinkedIn page. To learn more and order magicJack for BUSINESS, visit magicjackforbusiness.com or call 888-652-4976.

About magicJack for BUSINESS
magicJack for BUSINESS, a subsidiary of VoIP pioneer magicJack VocalTec, Ltd. (Nasdaq:CALL), is the smart business choice for savvy SMBs. With global headquarters located in Alpharetta, Georgia, magicJack for BUSINESS leverages its ultra-low cost network infrastructure and proprietary telecom software to deliver an easy-to-use business internet phone system tailored to meet the unique needs of SMBs. For more information, please visit magicjackforbusiness.com or call 888-652-4976.

About magicJack VocalTec Ltd.
magicJack VocalTec Ltd. (Nasdaq:CALL), the inventor of magicJack and a pioneer in Voice over IP (VoIP) technology and services, is a leading cloud communications company. With its easy-to-use, low cost solution for telecommunications, the Company has sold more than 10 million award-winning magicJack devices, now in their third generation, and holds more than 30 technology patents.  magicJack is one of the largest-reaching CLECs (Competitive Local Exchange Carrier) in the United States in terms of area codes available and number of states in which it is certified.

In March 2016, magicJack VocalTec Ltd. acquired Broadsmart, a leading hosted UCaaS (Unified Communication as a Service) provider for medium-to-large multi-location enterprise customers. Broadsmart has a track record of designing, provisioning and delivering complex UCaaS solutions to blue chip corporate customers on a nationwide basis. Broadsmart has expertise in servicing enterprises with hundreds-to-thousands of locations.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements about our launch of magicJack for BUSINESS; the ease of use and set up of magicJack for BUSINESS; its features, flat rate offering, connectivity uptime and customer support; our belief regarding the key benefits of the magicJack for BUSINESS offering; our expectation that magicJack for BUSINESS represents a new, organic revenue stream which leverages our core assets; and our belief that magicJack for BUSINESS will bring small-to-medium sized businesses a powerhouse solution of VoIP benefits while keeping their costs low and not sacrificing quality.  Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These factors include, among other things: our ability to successfully monetize our magicJack for BUSINESS offering and market it globally; our customer acceptance rate and customer turnover rate; any factors that may adversely affect our connectivity uptime and the quality of our VoIP service; changes to our business resulting from increased competition; changes in general economic, business, political and regulatory conditions; availability and costs associated with operating our network and business and our ability to control costs; potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies; the degree of legal protection afforded to our products; and the various other factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

INVESTOR RELATIONS CONTACT:

Seth Potter                   
561-749-2255
ir@vocaltec.com
Friday, August 19th, 2016 Uncategorized Comments Off on $CALL #magicJack for BUSINESS Opens Corporate HQ in #Atlanta Area

$ESIO Selects #MichaelBurger to be next #President and #CEO

Experienced technology executive to succeed Ed Grady on October 3rd

PORTLAND, Ore., Aug. 19, 2016  — Electro Scientific Industries, Inc. (Nasdaq:ESIO), an innovator of laser-based manufacturing solutions for the microtechnology industry, today announced that Michael Burger, former CEO of Cascade Microtech, Inc., will join as President and CEO of the Company and will succeed Edward C. Grady on October 3, 2016. Michael will also join the Board of Directors on the same date.

“We are fortunate to have been able to secure the services of Michael Burger as our new President and CEO,” said Richard Wills, Chairman of the Board of ESI. “Michael has over 30 years of broad industry and technology leadership experience, most recently as the successful President and CEO of Cascade Microtech Inc.”  Prior to his role at Cascade, Michael served as a Board member of Viasystems Inc. following its acquisition of Merix Corporation, where he served as President, Chief Executive Officer and Director.  While at Cascade, Michael was recognized as the 2014 Technology Executive of the Year by the Technology Association of Oregon. Wills continued, “We are very pleased to find an executive whose experience in technology is directly applicable to ESI’s strategy to expand in the PCB, ICP and related micromachining markets.”

“I look forward to taking the lead at ESI,” said Mr. Burger. “The company has a long history of technology and market leadership. The company has made great progress to get back on a growth and profitability path and I believe we will continue to have many exciting opportunities in the future.”

“We continue to be grateful to Ed for his outstanding leadership at ESI, in particular his willingness to step in from the Board of Directors to change the strategic direction and turnaround the financial performance of the company,” continued Mr. Wills. “We are delighted that Ed will continue to make significant contributions and remain on ESI’s Board of Directors.”

In connection with his hire, the Compensation Committee of the Board of Directors of the Company approved awards to Mr. Burger of 248,565 performance-based restricted stock units and 229,445 time-based restricted stock units, 76,575 of which were an inducement grant outside of a shareholder-approved plan, all effective his first day of employment. The inducement award will vest 25% on each of the first four anniversaries of his first day of employment. The other terms of Mr. Burger’s compensation will be described in a Current Report on Form 8-K to be filed by the Company.

About ESI, Inc.
ESI’s integrated solutions allow industrial designers and process engineers to control the power of laser light to transform materials in ways that differentiate their consumer electronics, wearable devices, semiconductor circuits and high-precision components for market advantage. ESI’s laser-based manufacturing solutions feature the industry’s highest precision and speed, and target the lowest total cost of ownership. ESI is headquartered in Portland, Oregon, with global operations and subsidiaries in Asia, Europe and North America. More information is available at www.esi.com.

ESI
Brian Smith
503-672-5760
smithb@esi.com
Friday, August 19th, 2016 Uncategorized Comments Off on $ESIO Selects #MichaelBurger to be next #President and #CEO

$EXPI @eXpRealty Launches in #Alaska

BELLINGHAM, WA — (August 19, 2016) – eXp World Holdings, Inc. (OTCQB: EXPI) today announced that eXp Realty has commenced real estate brokerage operations in the State of Alaska. The company is now operational in 41 states; Alberta, Canada; and, in the District of Columbia. Brokerage operations for eXp Realty in Alaska will be overseen by Brandon Tatum and Frank Zellers.

“Frank and I are excited to have the opportunity to bring eXp Realty to Alaska,” said Tatum, who joins the Company after serving as CEO and Broker for the Alaska Homes Group in Anchorage. “We’re looking forward to introducing the concept of agent-ownership and the idea that you can work alongside with and build relationships with some of the best agents in the business on a daily basis without having to go to a physical office or travel by plane or boat.”

Earlier this week, the Company filed its quarterly Form 10-Q in which it reported record year-over-year gains in revenues (137%) and agent count (111%).

“We are fortunate to have two experienced, talented, and credible leaders in place as we enter the Alaska market and and look forward to offering new opportunities to and welcoming entrepreneurial professionals across the state into our community,” said eXp Realty Founder, Glenn Sanford.

Brandon Tatum can be reached at: brandon.tatum@exprealty.com

Frank Zellers can be reached at: frank.zellers@exprealty.com

About eXp World Holdings, Inc.

eXp World Holdings, Inc. is the holding company for a number of companies most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage® as a full-service real estate brokerage providing 24/7 access to collaborative tools, training, and socialization for real estate brokers and agents through its 3-D, fully-immersive, cloud office environment. eXp Realty, LLC and eXp Realty of Canada, Inc. also feature an aggressive revenue sharing program that pays agents a percentage of gross commission income earned by fellow real estate professionals who they attract into the Company.

eXp World Holdings, Inc. also owns 89.4% of First Cloud Mortgage, Inc. a Delaware corporation launched in 2015 and now licensed to originate mortgages in Arizona, California, Virginia and New Mexico. First Cloud Mortgage has positioned itself as a Planet Friendly Mortgage Company via the purchase of carbon offsets for homeowners offsetting the first year of the Carbon Footprint of the typical home on each mortgage originated through First Cloud Mortgage, Inc.

As a publicly-traded company, eXp World Holdings, Inc. uniquely offers professionals within its ranks opportunities to earn equity awards for production and contributions to overall company growth.

For more information you can follow eXp World Holdings, Inc. on Twitter, LinkedIn, Facebook, YouTube, or visit eXpWorldHoldings.com. For eXp Realty please visit: eXpRealty.com and for First Cloud Mortgage, Inc. check out FirstCloudMortgage.com.

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to revise or update them. These statements include, but are not limited to, statements about the Company’s expansion, revenue growth, operating results, financial performance and net income changes. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; and other risks detailed from time to time in the Company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Annual Report on Form 10-K.

Investor Relations Contact Information:
Glenn Sanford
Chairman & CEO
eXp World Holdings, Inc.
glenn@expworldholdings.com
360-389-2426

Trade and Media Contact Information:
Jason Gesing
CEO
eXp Realty
jason@exprealty.com
617-970-8518

Friday, August 19th, 2016 Uncategorized Comments Off on $EXPI @eXpRealty Launches in #Alaska

$VUZI #AR #VR #Partnership w/ #Pristine Extended

ROCHESTER, N.Y., Aug. 18, 2016  — Vuzix® Corporation (NASDAQ: VUZI), a leading supplier of Smart Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets, is pleased to announce that Pristine, Austin-based developer of the EyeSight wearable software platform, has joined the Vuzix Industrial Partner (VIP) program. As a Vuzix VIP, Pristine has received one of the first early access Vuzix M300 Smart Glasses, and will bring EyeSight, its hands-free video collaboration platform to Vuzix’ latest hardware. The Vuzix M300 represents the next generation of smart glasses, designed to address customer feedback from more than two years of productive use of the M100 in the field.

“We are extremely excited about the M300’s raw power and innovative new features,” said Mark Troutfetter, Vice President of Engineering at Pristine. “As our EyeSight platform has matured to support the needs of global enterprises, we’ve pushed the legacy smart glass devices to their limits. The M300’s huge performance advancements and enterprise-focused design features make it the perfect device to empower the next wave of wearable innovation for our customers.”

With EyeSight, Pristine’s market opportunity encompasses organizations that rely on a distributed, skilled workforce–including companies in insurance, healthcare, manufacturing, inspection and certification, and field services. Powered by EyeSight, users can use verbal, hands-free commands to interact with their smart glasses, request support from an expert located anywhere around the world, and receive real-time coaching and assistance via secure first-person video streaming.

Pristine’s selection as a VIP follows the announcement last year that the two companies had partnered to optimize EyeSight for Vuzix’ M100 Smart Glasses. Pristine rapidly deployed the M100 to several enterprise customers, dramatically improving how those companies’ front-line field professionals collaborated with remote specialists.

“We are pleased that Pristine has become a VIP,” said Paul Travers, President and CEO of Vuzix. “EyeSight is a cutting edge solution that really shows how much technology can improve productivity and communication for enterprise users.”

“With Vuzix, we are able to dramatically improve returns on invested capital for our customers. We are excited to be a part of the VIP program and expect to deliver even greater productivity advances to our enterprise customers with the M300,” said Peter Evans, CEO of Pristine. He added, “Demand for the combination of EyeSight and the M300 is already high, both from companies new to wearable innovation, as well as existing customers.”

Advance access to the Vuzix M300 Smart Glasses enables Pristine to integrate EyeSight with the new device, and make it generally available when Vuzix M300 ships to customers early this fall. “We began using EyeSight with Vuzix M100 smart glasses in early 2015 to enable nurses to live-stream audio and video during their patient care visits to a remote wound care expert or physician,” said Lora Epperly, Director of Business Development and Care Innovations for Commonwealth Care of Roanoke, Inc. (CCR). “The results have been very impressive and we’re excited about the arrival of the M300, with its new sleeker design and improved capabilities, so much so that we’ve already placed pre-orders to be first in line to receive it.”

To learn more about the M300, or becoming a VIP, please contact Lance Anderson, VP of Enterprise Sales, at lance_anderson@vuzix.com.

About Pristine

Pristine is focused on enabling the deskless worker with enterprise software solutions for smart glasses. EyeSight, Pristine’s flagship platform, multiplies the skills, knowledge, and capability of a distributed workforce by enabling  experts to be available anywhere, on-demand. Pristine’s collaborative solutions allow companies to instantly scale the knowledge of these experts, and in doing so, dramatically improve how you utilize these valuable human resources. EyeSight is available across every platform: Mac, PC, iPhone, iPad, Android, and Vuzix, and is HIPAA compliant. More information can be found on Pristine’s website (www.pristine.io), Pristine’s blog (www.pristine.io/blog), and by following @PristineIO on Twitter (www.twitter.com/pristineio).

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets. The Company’s products include personal display and wearable computing devices that offer users a portable high quality viewing experience, provide solutions for mobility, wearable displays and virtual and augmented reality. Vuzix holds 43 patents and 23 additional patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2016 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK and Tokyo, Japan.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to, among other things, the new M300 Smart Glasses, the partnership with Pristine and their success with the M300, and the Company’s leadership in the Smart Glasses, VR and AR industry. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Investor and Media Relations Contact:

Andrew Haag
Managing Partner
IRTH Communications
vuzi@irthcommunications.com
1-866-976-4784

Vuzix Corporation
25 Hendrix Road, Suite A West
Henrietta, NY 14586 USA
Investor Information – Grant Russell
IR@Vuzix.com
Tel: (585) 359-7562
www.vuzix.com

For further sales, and product information, please visit:

North America:
http://www.vuzix.com/contact/

Europe/UK:
https://www.vuzix.eu/contact/

Asia:
http://www.vuzix.jp/contact.html

Thursday, August 18th, 2016 Uncategorized Comments Off on $VUZI #AR #VR #Partnership w/ #Pristine Extended

$CTHR #ForeverOne Moissanite Launches on #Gemvara

Charles & Colvard, Ltd. (NASDAQ: CTHR), the original and leading worldwide source of moissanite, today announced their partnership with Gemvara, a leading online retailer of customizable fine jewelry. Gemvara, a Richline Group company, will showcase Charles & Colvard Forever One™ on its unique, world-class e-commerce platform. Forever One moissanite is a colorless gem in the coveted D-E-F range that is known for its unsurpassed fire and brilliance.

“Launching conflict-free moissanite from Charles & Colvard continues our mission of providing customers with the selection and choice they need to customize their perfect piece of jewelry. We offer customers 30 gemstones and 9 metals to select from for almost all of our thousands of designs, and we’re excited to have moissanite as our newest option. The stone offers more brilliance than a diamond at a lower price point and with clear conflict-free status,” said Matt Nichols, Gemvara’s CEO.

“We’re thrilled to be distributing our Forever One moissanite through Gemvara. This is part of our omni-channel strategy; being everywhere the modern consumer is shopping. Gemvara is an ideal partner for Charles & Colvard given their appeal to the bridal and millennial-oriented customer,” said Suzanne Miglucci, president and CEO of Charles & Colvard. “We’re pleased to be an integral part of Gemvara’s innovative, next generation, personalized jewelry shopping experience.”

The consumer landscape is continuously changing. Charles & Colvard believes that Millennials and Gen Xers have the buying power and are driving revolution in the jewelry sector. Gemvara continues to be a leader in this industry shift with the addition of Charles & Colvard Forever One moissanite, which eliminates the artificial distinctions between value and beauty and offers socially responsible fine jewelry to the consumer who is thinking beyond traditional choices such as diamonds.

Each Charles & Colvard Created Moissanite® gemstone comes with a Certificate of Authenticity and a Limited Lifetime Warranty from Charles & Colvard. Laser inscriptions are engraved on Forever One gemstones, attesting that each gemstone meets the highest standards of Charles & Colvard’s quality specifications.

For more information on Charles & Colvard Created Moissanite, please visit www.charlesandcolvard.com.

About Charles & Colvard, Ltd.

Charles & Colvard, Ltd., based in the Research Triangle Park area of North Carolina, is the world’s only source of Forever Classic™, Forever Brilliant®, and Forever One™ moissanite gemstones, which surpass the fire and brilliance of diamonds. Moissanite is unique, available in three color grades (colorless, near-colorless, and faint color), and created from silicon carbide (SiC) crystals for fine jewelry. Charles & Colvard Created Moissanite® is sold with a Certificate of Authenticity and Limited Lifetime Warranty to wholesale distributors, manufacturers, retailers, TV shopping networks, and designers as loose stones or set in a wide variety of quality metal setting options. Charles & Colvard, Ltd. also sells direct to consumers through its wholly owned operating subsidiary, Moissanite.com, LLC. Charles & Colvard, Ltd.’s common stock is listed on the NASDAQ Global Select Market under the symbol “CTHR.” For more information, please visit www.charlesandcolvard.com.

About Gemvara

Gemvara is the revolutionary leader of fine jewelry shopping online. Every piece of heirloom-quality jewelry is skillfully handcrafted to order. Gemvara combines the values of traditional jewelry creation with modern technology to truly provide shoppers with fine jewelry exactly the way they want it, plus a shopping experience that is creative and fun. Gemvara is headquartered in Boston, MA and was acquired by the Richline Group in April of 2016.

 

LaRue PR
Jessy Fofana, 732-667-7777
jessy@laruepr.com

Thursday, August 18th, 2016 Uncategorized Comments Off on $CTHR #ForeverOne Moissanite Launches on #Gemvara

$NFEC New #China Contract Signed

SHENYANG, China, Aug. 18, 2016  — NF Energy Saving Corporation (NFEC) (“NF Energy” or the Company), a leading energy saving service solutions provider for China’s power, petrochemical, coal, metallurgy, construction and municipal infrastructure development industries, announced that it recently signed a total $600,000 sales contracts with four companies in China.

The four companies are the hydroelectric Retrofit project of Anhui Huangneng Liangting Co., Ltd, the condenser circulating water project of Jiangsu Shenhua Guohua Chengjiagang Co., Ltd, the Zambian exported project of Shandong electric power construction Co., Ltd, and the pipeline reinforcement project of Shenzhen Jinrun construction Co. Ltd.

Among these companies, Anhui Huangneng Liangting Co., Ltd, Jiangsu Shenhua Guohua Chengjiagang Co., Ltd and Shandong electric power construction Co., Ltd are stated-owned companies.

The total order includes electric butterfly valves and hydraulic control butterfly valves with DN400-DN2800. All products are anticipated to be delivered between September and October, 2016.

About NF Energy Saving Corporation

NF Energy Saving Corporation (NASDAQ:NFEC) is a China-based provider of integrated energy conservation solutions utilizing energy-saving equipment, technical services and energy management re-engineering project operations to provide energy saving services to clients. The Company’s customers are mainly concentrated in the electrical generation (large-scale thermal power generation, hydroelectric power, and nuclear power), water supply, and heat supply industries. The majority of revenues are from energy efficient flow control solutions including equipment and energy efficiency project services. For more information, visit http://www.nfenergy.com.

Safe Harbor Statement

The statements contained herein that are not historical facts are considered “forward-looking statements.” Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, statements regarding the efficacy of investment in research and development are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the effect of political, economic, and market conditions and geopolitical events; legislative and regulatory changes that affect our business; the availability of funds and working capital; the actions and initiatives of current and potential competitors; investor sentiment; and our reputation. We do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events, which may cause actual results to differ from those expressed or implied by any forward-looking statements. The factors discussed herein are expressed from time to time in our filings with the Securities and Exchange Commission available at http://www.sec.gov.

Andy Gao
Phone Number: +86-24-25609775
Email: info@nfenergy.com

Thursday, August 18th, 2016 Uncategorized Comments Off on $NFEC New #China Contract Signed

$SHLM Chairman #JosephGingo Named #CEO & #President

– Gingo to Initiate Comprehensive Review of Company’s Business Plan and Global End Markets in Light of Fiscal 2016 Performance – Board and Bernard Rzepka, President and Chief Executive Officer, Have Mutually Agreed He Will Relinquish His Officer Role and Directorship Role

AKRON, Ohio, Aug. 18, 2016  — The Board of Directors of A. Schulman, Inc. (Nasdaq-GS: SHLM) today announced that Chairman Joseph M. Gingo has been named chief executive officer and president, effective immediately. Gingo (71) had previously served in this capacity from 2008 through 2014. The Board and Bernard Rzepka (56), president and chief executive officer, have mutually agreed that he will relinquish his officer role and his directorship role.

“Joe led this Company through a remarkable seven-year renaissance as its chief executive officer and the Board is confident that he will restore A. Schulman’s operational and financial performance to the high level our shareholders expect,” said David Birney, lead independent director. “We thank Bernard for his dedicated service to A. Schulman during the last 24 years. His many contributions throughout his career with the Company should not be overlooked or minimized in light of this transition.”

According to Gingo, the Company will undertake a comprehensive review of its business plan, as well as near- and longer-term global end market trends. The Company intends to retain a leading advisory firm to assist in this review process.

“Like our fellow shareholders, the Board is not satisfied with the Company’s less-than-optimal performance throughout fiscal 2016,” said Gingo. “In light of last week’s earnings guidance revision, the time has come to conduct a comprehensive review of our business plan and strategic execution.”

Gingo continued to say that he is committed to conducting a deliberate and unvarnished assessment as promptly as practical. “Our intent is to provide additional information on our review as appropriate, when appropriate,” he said. “We will not, however, speculate on any potential outcomes from this assessment or the timetable for it. The goal is to verify our market intelligence, refine our vision and improve our execution.”

The Company expects to release fiscal 2016 fourth-quarter and full-year results, as well as fiscal 2017 earnings guidance, after the market closes on Wednesday, October 26, 2016. The Company will hold its fiscal 2016 fourth-quarter and full-year earnings conference call on Thursday, October 27, 2016 at 10 a.m. Eastern time.

About A. Schulman, Inc.
A. Schulman, Inc. is a leading international supplier of high-performance plastic compounds and resins headquartered in Akron, Ohio. Since 1928, the Company has been providing innovative solutions to meet its customers’ demanding requirements. The Company’s customers span a wide range of markets such as packaging, mobility, building & construction, electronics & electrical, agriculture, personal care & hygiene, sports, leisure & home, custom services and others. The Company employs approximately 4,900 people and has 57 manufacturing facilities globally. A. Schulman reported net sales of approximately $2.4 billion for the fiscal year ended August 31, 2015. Additional information about A. Schulman can be found at www.aschulman.com.

Cautionary Statements
A number of the matters discussed in this document that are not historical or current facts deal with potential future circumstances and developments and constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts and relate to future events and expectations. Forward-looking statements contain such words as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Forward-looking statements are based on management’s current expectations and include known and unknown risks, uncertainties and other factors, many of which management is unable to predict or control, that could cause actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking statements. Important factors that could cause actual results to differ materially from those suggested by these forward-looking statements, and that could adversely affect the Company’s future financial performance, include, but are not limited to, the following:

  • worldwide and regional economic, business and political conditions, including continuing economic uncertainties in some or all of the Company’s major product markets or countries where the Company has operations;
  • the effectiveness of the Company’s efforts to improve operating margins through sales growth, price increases, productivity gains, and improved purchasing techniques;
  • competitive factors, including intense price competition;
  • fluctuations in the value of currencies in areas where the Company operates;
  • volatility of prices and availability of the supply of energy and raw materials that are critical to the manufacture of the Company’s products, particularly plastic resins derived from oil and natural gas;
  • changes in customer demand and requirements;
  • effectiveness of the Company to achieve the level of cost savings, productivity improvements, growth and other benefits anticipated from acquisitions, joint ventures and restructuring initiatives;
  • escalation in the cost of providing employee health care;
  • uncertainties and unanticipated developments regarding contingencies, such as pending and future litigation and other claims, including developments that would require increases in our costs and/or reserves for such contingencies;
  • the performance of the global automotive and oil and gas markets as well as other markets served;
  • further adverse changes in economic or industry conditions, including global supply and demand conditions and prices for products;
  • operating problems with our information systems as a result of system security failures such as viruses, cyber-attacks or other causes;
  • our current debt position could adversely affect our financial health and prevent us from fulfilling our financial obligations;
  • integration of acquisitions, including most recently Citadel, with our existing business, including the risk that the integration will be more costly or more time consuming and complex or simply less effective than anticipated;
  • our ability to achieve the anticipated synergies, cost savings and other benefits from the Citadel acquisition;
  • substantial time devoted by management to the integration of the Citadel acquisition; and
  • failure of counterparties to perform under the terms and conditions of contractual arrangements, including suppliers, customers, buyers and sellers of a business and other third parties with which the Company contracts.

The risks and uncertainties identified above are not the only risks the Company faces. Additional risk factors that could affect the Company’s performance are set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015. In addition, risks and uncertainties not presently known to the Company or that it believes to be immaterial also may adversely affect the Company. Should any known or unknown risks or uncertainties develop into actual events, or underlying assumptions prove inaccurate, these developments could have material adverse effects on the Company’s business, financial condition and results of operations. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You should consult any further disclosures which are made on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

Thursday, August 18th, 2016 Uncategorized Comments Off on $SHLM Chairman #JosephGingo Named #CEO & #President

$MKGI Launches Premium Service for #AlternativeLodging Listings

Provides Property Owners With Tools to Adequately Compete With Travel Industry Suppliers

WESTON, FL–(Aug 18, 2016) – Monaker Group (OTCQB: MKGI), a technology-driven travel company focused on the alternative lodging rental (ALR) market, announced today that it has developed and launched a Premium Service for property owners offering participants a solution for time management and property booking optimization.

Monaker’s Premium Service for property owners was developed on the basis that travel industry suppliers (airlines, hotels, car rental companies) have the tools to actively manage their rates on a minute-by-minute basis allowing them to react to competitive pricing, utilization and other market conditions in efforts to maximize revenues. Unfortunately, the homeowner often lacks the time and market knowledge to compete. The Premium Service is designed to help property owners address these inadequacies by providing reservation services, pricing optimization and global distribution of their property. Key elements include:

  • Management and control of the homeowner’s calendar resulting in real-time booking capability.
  • Management of all guest communications from booking to checkout including booking inquiries, booking requests and emergencies around the clock, potentially saving many hours per week typically required managing property listings and bookings.
  • Providing global distribution across major global booking platforms and markets published with many language conversions and offered in all major currencies worldwide.
  • Management of property pricing with customized revenue & pricing management tools where property pricing is updated daily to reflect real-time market conditions.

Monaker Chairman and Chief Executive Officer, Bill Kerby, stated, “The Alternative Lodging (“AL”) market is known to be one of the fastest growing segments in the Travel space. In fact, Research and Markets issued a Report earlier this year stating ‘the global vacation rental market will reach $169.7 billion by 2019.‘ There are millions of property owners around the globe seeking a prudent and manageable option to post their vacation rental properties as Alternative Lodgings. We at Monaker have developed a solution that we believe will give the property owner an opportunity to increase their property booking revenue nearly 50%, while reducing the time required to manage the property by 10 hours per week. In addition, this inventory will give Monaker a boost in attracting more individual and possible unique properties to our already growing AL inventory.

“The Premium Service provides property owners seeking to rent their unit(s) expanded distribution across all major channels, language conversions for a worldwide reach, dynamic pricing and revenue management tools, and reservations services. Pilot marketing for the Premium Service clients suggests they could expect up to a 50% or greater increase in year over year booking revenue with a significant reduction in the time required to manage their property. When Premium Service customers provide the Company the physical address of the rental property, they will receive a timely custom analysis for the property, providing an estimate of expected growth in incremental year over year rental revenue by participating and listing in the Premium Service.

“Property owners already working with other major booking platforms that list or join the Monaker Premium Service should expect to receive a complete audit of the booking history applying the Monaker team’s expertise in optimizing the property listing(s) for occupancy and booking revenue, while managing the listings and associated reservations. Monaker’s technology, platform architecture and partnerships position the Premium Service listings on up to 50 major global booking platforms in multiple languages worldwide.

Monaker Chairman and CEO Bill Kerby concluded, “The Premium Service leverages our deep expertise in inventory acquisition, reservations services, technology and distribution. We see this as a win-win scenario, ultimately delivering more real-time bookable inventory to the market, and greater choice in inventory to travel consumers.”

About Monaker:

Monaker Group is a technology driven Travel Company with multiple divisions and brands, leveraging more than 60 years of operation in leisure travel. Monaker’s flagship is NextTrip.com, the industry’s first real time booking engine featuring alternative lodging (vacation home rentals, resort residences and unused timeshares) as well as a vast array of airlines, hotels, cruises, rental cars, tours and concierge services all combined in one platform to give customers the power of choice when booking their vacations. With key partnerships and established travel brands used as cornerstones, the Company’s mission is to continue to expand offerings to become the “one stop” vacation center. Headquartered in South Florida, the Company employs a dedicated team of travel and technology professionals. For more information visit the company’s website at www.monakergroup.com

Safe Harbor Statement:

This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker Group. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, or the expectations of future growth may not be realized. These forward-looking statements are made only as of the date hereof, and Monaker Group, undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker Group’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company’s Annual Report on Form 10-K for the period ended February 29, 2016 which has been filed with the SEC and is available at the SEC’s website at www.sec.gov.

Monaker Group
Attention:
Richard Marshall
Director of Corporate Development
Email: rmarshall@monakergroup.com
Tel: (954) 888-9779

Chesapeake Group
Investor Relations
Tel: (410) 825-3930

Thursday, August 18th, 2016 Uncategorized Comments Off on $MKGI Launches Premium Service for #AlternativeLodging Listings

$MESO Strengthens Key #US #Patent #Portfolio in Rheumatic Diseases Like #Arthritis

NEW YORK and MELBOURNE, Australia, Aug. 17, 2016  — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that its intellectual property portfolio covering the use of its Mesenchymal Precursor Cells (MPCs) in the treatment of rheumatic diseases, including rheumatoid arthritis (RA), has been strengthened by the granting of a key patent by the United States Patent and Trademark Office (USPTO).

The Company’s patent estate in the US for the treatment of RA and related conditions comprises the newly and recently granted patents, US 9,381,216 and US 9,265,796, which cover treatment of rheumatic diseases by administration of STRO-1 positive MPCs. Together with patents covering MPC compositions-of-matter, US 7,122,178 and US 8,367,405, these granted patents provide Mesoblast with commercial rights in the US through to July 4, 2032 for the use of MPCs in the treatment of various rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, sacroiliitis, and arthritis associated with inflammatory bowel disease (enteric arthritis and Reiter’s syndrome).

Additionally, the granted claims cover the use of these cell populations to reduce levels of inflammatory cytokines TNF-alpha, interleukin-6, and interleukin-17, all established mediators of inflammatory arthritis in rheumatic diseases. Further patent term extension may occur along with regulatory exclusivity extensions.

About Mesoblast’s Phase 2 Trial In Rheumatoid Arthritis

Biologic refractory RA patients who have received prior anti-TNF or other biologic agents continue to have active inflammatory pathways, and the broad, concomitant targeting of multiple cytokine networks by MPCs may result in clinically meaningful outcomes in this patient group.

As recently announced, results of Mesoblast’s 48-patient randomized, placebo-controlled Phase 2 trial in biologic refractory RA showed that a single intravenous infusion of its proprietary allogeneic MPC product candidate, MPC-300-IV, was well tolerated, without serious adverse events, and demonstrated a dose-related improvement in clinical symptoms, physical function, and disease activity relative to placebo through the 12 week primary endpoint.

Dr. Allan Gibofsky, Professor of Medicine and Public Health at Weill Cornell Medical College and Attending Rheumatologist at Hospital for Special Surgery in New York, stated: “The trial used standardized parameters consistent with United States Food and Drug Administration (FDA) guidance for RA product development. Importantly, there was consistency observed in the dose-related responses for clinical symptoms, physical function and disease activity parameters at 12 weeks in line with the trial’s pre-specified efficacy endpoints.”

The primary objective of the study was to evaluate safety and tolerability of a single intravenous MPC infusion in biologic refractory RA patients through a 12 week primary endpoint. Additional objectives were to evaluate pre-specified clinical efficacy endpoints at the primary 12 week timepoint, as well as to assess the onset and time course of effect within the first 12 weeks and subsequent durability of effects and safety profile through the full 52 week study. The American College of Rheumatology (ACR) response, a validated measure of clinical symptoms and signs, and DAS28, a validated measure of disease activity, were assessed at baseline and weeks 1, 4, 8 and 12. The health assessment questionnaire disability index (HAQ-DI), a validated measure of function, was assessed at baseline and weeks 4 and 12.

All analyses and test methods for the trial’s efficacy endpoints were pre-specified in the trial’s Statistical Analysis Plan (SAP), including a pre-specified analysis on the key subgroup based on 1-2 prior biologics. No post hoc analyses were conducted.

The SAP was submitted to the FDA before any analyses were conducted. The SAP specifically stated that no adjustments for multiple testing (multiplicity) would be applied because the efficacy analyses in this study were exploratory and the trial was not powered for efficacy. For continuous variables where changes from baseline were reported, the Least Squares of the Mean (ANCOVA) was utilized in order to adjust for baseline differences between groups.

About MPC Mechanisms of Action in Rheumatoid Arthritis

There are at least two mechanisms of action (MOA) by which MPC-300-IV may impact on clinical outcomes in rheumatoid arthritis through concomitant inhibition of multiple cytokine networks:

1. Immunomodulation: Pro-inflammatory monocytes/macrophages and activated T cells are involved in the pathogenesis of RA via joint inflammation and secretion of multiple proinflammatory cytokines. In preclinical studies, activation of MPCs by these pro-inflammatory cytokines through specific surface receptors results in release by MPCs of anti-inflammatory mediators including PGE2 and IDO which act on inflammatory target cells. Allogeneic human MPCs secreting PGE2 and IDO, when co-cultured with donor immune cells, switch proinflammatory monocytes producing TNF-alpha or IL-6 to an anti-inflammatory phenotype producing IL-10, and switch pro-inflammatory T cells producing IL-17 to anti-inflammatory FoxP3 Tregs producing IL-10.

2. Synoviocyte Inhibition: Pro-inflammatory synoviocytes in the RA joint proliferate highly and secrete multiple cytokines involved in RA disease pathogenesis. The biomolecules PGE2 and TGF-beta, secreted by MPCs following cell surface signalling by inflammatory cytokines, act directly on RA synoviocytes to inhibit the pleiotropic signalling molecule NFkappaB, resulting in reduced synoviocyte proliferation and decreased production by the synoviocytes of the pro-inflammatory factors TNF-alpha, IL-1, IL-6, IL-8, MCP-1, and various metalloproteinases involved in joint inflammation and destructive pathology.

In large animal studies, a single intravenous infusion of Mesoblast’s allogeneic MPCs resulted in concomitant inhibition of TNF-alpha, IL-6 and IL-17 inflammatory pathways in the inflamed joints, and substantially ameliorated clinical disease.

As noted above, Mesoblast’s granted patents cover reduction in the levels of inflammatory cytokines such as TNF-alpha, interleukin-6, and interleukin-17, all established mediators of inflammatory arthritis in rheumatic diseases.

About RA
RA is a chronic autoimmune disease of unknown etiology, affecting approximately one percent of the global population. The disease is attributed to chronic inflammation affecting the synovial membrane of multiple joints, which eventually leads to cartilage and bone destruction. The health-related quality of life in patients with RA is significantly impaired by pain, fatigue, and decline in musculoskeletal function. RA is associated with an increased risk of cardiovascular disease and mortality.

About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

For further information, please contact:

Schond Greenway
Investor Relations
Mesoblast
T: +1 212 880-2060
E: schond.greenway@mesoblast.com

Julie Meldrum
Corporate Communications
Mesoblast
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Wednesday, August 17th, 2016 Uncategorized Comments Off on $MESO Strengthens Key #US #Patent #Portfolio in Rheumatic Diseases Like #Arthritis

$NVIV Fifth Patient Conversion in #INSPIRE #Study of #NeuroSpinalScaffold™

– Conversion Rate to Date is Four Times the Rate in Natural History Databases –

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the ninth patient implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between the two- and three-month evaluations. This is the fifth out of the eight patients (62.5% conversion rate) in follow-up to have had an AIS grade improvement to date. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries have an AIS grade improvement by six months post-injury.* Historical conversion rates are lowest for patients with high thoracic (T2-T5) injuries, with fewer than 8% of patients converting by six months post-injury. The neurological level of injury for this patient was T4.

“The evidence obtained to date in the INSPIRE study is tremendously encouraging. It has been rewarding to be involved in the study and to observe this patient’s recovery to date, and I hope that the patient continues to make progress,” said Stuart Lee, M.D. Dr. Lee, Principal Investigator at Vidant Medical Center in Greenville, NC performed the ninth patient implantation procedure.

“Having five patients improve AIS grades so early in the INSPIRE study is a fantastic achievement and a major milestone for InVivo,” said Mark Perrin, Chief Executive Officer and Chairman. “If we continue to observe AIS conversions at a similar rate, we will dramatically exceed the Objective Performance Criterion (OPC) measure of study success. Our current conversion rate is four times the rate in natural history databases, which is extremely encouraging. We look forward to completing the INSPIRE study as quickly as possible and applying for an HDE in 2017.”

The OPC measure of success for the INSPIRE study is defined as five (25%) or more of 20 evaluable patients in the study having improved by at least one AIS grade at the six months post-implantation assessment. If all five converted patients to date do not revert to AIS A before reaching the six month assessment and are deemed evaluable at the end of the study, then the OPC will have been met.

About The INSPIRE Study

The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval. The FDA has recommended that InVivo include a control arm in the study as part of a Study Design Consideration. We are in discussions with the FDA on this recommendation, and we continue to believe that our current study design is sufficient to demonstrate safety and probable benefit in support of a HDE application for marketing approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, the potential achievement of OPC, the determination of whether patients are deemed evaluable and the expectation for application for an HDE. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

* Zariffa et al., Spinal Cord (2011); Lee et al., J. Spinal Cord Med. (2014); Fawcett et al., Spinal Cord (2007)

 

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

Wednesday, August 17th, 2016 Uncategorized Comments Off on $NVIV Fifth Patient Conversion in #INSPIRE #Study of #NeuroSpinalScaffold™

$TRIL Receives #FDA Clearance to Proceed With #TTI621 #ClinicalTrial

TORONTO, ONTARIO–(Aug. 17, 2016) – Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides. Patient enrollment is anticipated to commence by the end of the year. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies.

“The FDA’s acceptance of this IND application is another important milestone for our company, as the study of TTI-621 in select tumor types could lead to a more thorough understanding of its mechanism of action, and may bring us one step closer to a much needed treatment option for patients,” said Dr. Niclas Stiernholm, chief executive officer of Trillium Therapeutics. “We seek to gain insight into the tumor micro-environment before, during and after treatment with TTI-621. This will help us learn how to best use TTI-621 CD47 blockade in combination with other anti-cancer drugs and better design the commercial development path for this agent.”

In the multicenter, open-label, Phase 1 trial, TTI-621 will be delivered by intratumoral injection in patients with relapsed and refractory, percutaneously-accessible cancers. Patients will be enrolled in sequential dose cohorts to receive intratumoral injections of TTI-621 that increase in dose and dosing frequency to characterize safety, pharmacokinetics, pharmacodynamics and preliminary evidence of antitumor activity. In addition, detailed evaluation of serial, on-treatment tumor biopsies of both injected and non-injected cancer lesions will help characterize tumor microenvironment changes anticipated with CD47 blockade.

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, which reflect Trillium’s current expectation regarding future results, events or developments, including our expectation of initiating the solid tumor trial by the end of the year, our belief of improving our understanding of the mechanism of action, the tumor microenvironment, and how to best use TTI-621 in combination with other anti-cancer agents. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Company Contact: James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com

Investor and Media Relations: Mark Corbae
Canale Communications for Trillium Therapeutics
619-849-5375

Wednesday, August 17th, 2016 Uncategorized Comments Off on $TRIL Receives #FDA Clearance to Proceed With #TTI621 #ClinicalTrial

$SKYS Announces Potential Sale of Certain Assets Held by #SkySolar Japan

  • Sky Solar signs Letter of Intent to sell its interests in 152 MW of operating, under-construction, and shovel-ready solar projects in Japan, with expected consideration of JPY17 billion, subject to closing adjustments
  • Proceeds to be reinvested in additional solar projects in Japan, as well as other key target markets that meet Sky Solar’s investment return criteria.
  • Close of transaction is subject to completion of satisfactory due diligence and approval by Solar Partnership’s investment committee and execution of definitive documents.

HONG KONG, Aug. 17, 2016  — Sky Solar Holdings, Ltd. (NASDAQ:SKYS) (“Sky Solar” or the “Company”), a global developer, owner and operator of solar parks, today announced that the Company entered into a Letter of Intent with Solar Partnership Capital Ltd (“Solar Partnership” or “SPC”),  a non-affiliate of the Company in certain Japanese projects, pursuant to which Solar Partnership confirmed its intention to acquire interests it currently does not own in 152 MW of solar projects from Sky Solar Japan K.K. (“SSJ”) and to take on certain specified liabilities associated with respect to those projects (the “Transaction Assets”) for a total  purchase price of JPY17 billion (approximately $US165 million), subject to certain standard closing adjustments. All the other assets and liabilities of SSJ that do not constitute Transaction Assets will be transferred to a new entity.

The proceeds from the transaction are expected to be used to repay certain existing loans that were provided as part of SPC’s existing tokumei kumiai investment in SSJ, as well as to invest in selected opportunities in Japan and other key target markets.

Closing of the transaction is subject to approval by Solar Partnership’s investment committee, completion of satisfactory due diligence and mutual agreement and execution of definitive documents. The Letter of Intent terminates on August 31, 2016 but it may be extended by mutual consent. Both parties are working diligently to satisfy the conditions as quickly as possible.

Mr. Sanjay Shrestha, Chief Investment Officer of Sky Solar, and President of Sky Capital America commented, “We are very pleased to announce the potential sale of part of our solar asset portfolio in Japan. Through this transaction, we remain committed to the development of our remaining projects in Japan while also unlocking value from our 74 MW of completed solar projects and 78 MW of solar projects that have not yet been completed in Japan.  With the cash proceeds from this deal, we intend to further invest in solar development projects in Japan and other key target markets that meet our investment return criteria.”

About Sky Solar Holdings, Ltd.

Sky Solar is a global independent power producer (“IPP”) that develops, owns and operates solar parks and generates revenue primarily by selling electricity. Since its inception, Sky Solar has focused on the downstream solar market and has developed projects in Asia, South America, Europe, North America and Africa. The Company’s broad geographic reach and established presence across key solar markets are significant differentiators that provide global opportunities and mitigate country-specific risks. Sky Solar aims to establish operations in select geographies with highly attractive solar radiation, regulatory environments, power pricing, land availability, financial access and overall power market trends. As a result of its focus on the downstream photovoltaic segment, Sky Solar is technology agnostic and is able to customize its solar parks based on local environmental and regulatory requirements. As of March 31, 2016, the Company had developed 276 solar parks with an aggregate capacity of 259.1 MW and owned and operated 133.1 MW of solar parks.

Safe-Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release and the Company’s operations and business outlook contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to the following: the reduction, modification or elimination of government subsidies and economic incentives; global and local risks related to economic, regulatory, social and political uncertainties; resources we may need to familiarize ourselves with the regulatory regimes, business practices, governmental requirements and industry conditions as we enter into new markets; global liquidity and the availability of additional funding options; the delay between making significant upfront investments in the Company’s solar parks and receiving revenue; expansion of the Company’s business into the U.S. and China; risk associated with the Company’s limited operating history, especially with large-scale IPP solar parks; risk associated with development or acquisition of additional attractive IPP solar parks to grow the Company’s project portfolio; and competition. Further information regarding these and other risks is included in Sky Solar’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Sky Solar:

IR@skysolarholding.com

SKYS Investor Relations:

ICR, LLC
Vera Tang
(646) 277-1215
Vera.tang@icrinc.com
Wednesday, August 17th, 2016 Uncategorized Comments Off on $SKYS Announces Potential Sale of Certain Assets Held by #SkySolar Japan

$NYMX Announces #PrivatePlacement (s) of $2.24 Million

HASBROUCK HEIGHTS, N.J., Aug. 17, 2016  — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million. The investments totaled 965,649 shares at an average price of $2.32 with no warrants. The funds will be used for general corporate purposes. The majority of the investment came from long-term non-insider shareholders in the Company.

Erik Danielsen, CFO of Nymox said, “This additional funding from long-term supportive shareholders provides an extra cash cushion for our regulatory filing preparation activities currently underway. We are extremely pleased with the support we get from many of our long-term shareholders who share our assessment that the Company’s near-term prospects are excellent. Our fact-based confidence in Nymox’s future is also reflected in the significant ongoing buying of our shares in the open market by long-term shareholders and officers and directors of the company.”

Nymox recently announced that long-term BPH studies of the Company’s lead drug fexapotide showed excellent safety and efficacy results, in addition to a dramatic reduction in the long-term incidence of prostate cancer in the BPH studies compared to the expected incidence from comparable patient studies in the literature. Fexapotide treated patients also had significantly reduced long-term prostate cancer incidence compared to placebo-treated BPH patient controls.

Nymox CEO Paul Averback M.D. stated last week that further clinical trial results for fexapotide were expected to be reported in the very near future.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2015, and its Quarterly Reports.

 

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com
Wednesday, August 17th, 2016 Uncategorized Comments Off on $NYMX Announces #PrivatePlacement (s) of $2.24 Million

$AVGR Closes #PublicOffering

REDWOOD CITY, Calif., Aug. 16, 2016 — Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’s common stock at a price to the public of $3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,285,800 shares of Avinger’s common stock. The total net proceeds from the offering are estimated to be approximately $31.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Avinger.

The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses. Use of proceeds may also include the partial repayment of debt under the Company’s loan agreement with CRG Partners III L.P. and certain of its affiliated funds in order to cure potential non-compliance with the covenant in the loan agreement requiring that the Company achieve minimum revenue of $23.0 million in 2016. The Company does not have any agreements or commitments for any specific acquisitions at this time.

Canaccord Genuity and Cowen and Company are serving as the joint book-running managers for the offering, and BTIG and Stephens Inc. are acting as co-managers.

The offering was made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus supplement describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained at the SEC’s website at www.sec.gov or by contacting the Syndicate Department of Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at (617) 371-3900, by email at prospectus@canaccordgenuity.com, or by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There shall not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with PAD. PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular™ platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding, but not limited to, the expected net proceeds and expected uses of proceeds from the offering. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market conditions and future decisions regarding the Company’s use of cash resources; as well as the other risks described in the section entitled “Risk Factors” and elsewhere in our second quarter Form 10-Q filing made with the Securities and Exchange Commission on August 5, 2016. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

INVESTOR CONTACT 

Matt Ferguson
Avinger, Inc.
(650) 241-7917
ir@avinger.com
Tuesday, August 16th, 2016 Uncategorized Comments Off on $AVGR Closes #PublicOffering

$CASI Update #Phase2 #Trial Of #ENMD2076 in #Cancer

Study Meets Stage 1 Non-Futility Endpoint; Advances to Stage 2 Development

ROCKVILLE, Md., Aug. 16, 2016  — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today announced that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC) has met its Stage 1 endpoint of objective response for non-futility based on the pre-specified interim analysis criteria and will advance to Stage 2 development.

Rong Chen, M.D., CASI’s Chief Medical Officer, commented, “The trial is to evaluate safety and efficacy of ENMD-2076 as a single agent in a total of 29 locally-advanced or metastatic FLC patients. It uses a Simon’s optimal two-stage design to allow for an early determination of potential futility in the 16 patients of Stage 1. An additional 13 patients will be recruited in Stage 2 to allow an overall final analysis with sufficient power. Having met the Stage 1 endpoint, we will now advance the trial to Stage 2 development. Meanwhile, the Stage 1 remains ongoing with approximately one-third of the patients still under treatment. A full interim analysis will be conducted and reported after all 16 patients have reached study endpoint of responses.”

Ken Ren, Ph.D., CASI’s Chief Executive Officer, commented, “We are pleased to see our FLC trial advance into Stage 2, which upon completion will increase the amount of data of ENMD-2076 in FLC patients.  FLC is a life-threatening disease that typically affects young adults and is currently without any systemic treatment. Based on results to date, we are encouraged by the potential of ENMD-2076 to address the unmet medical needs of these patients.  We are thankful to our investigators for their dedication to the program and to our FLC patients who make the trial meaningful and drive our purpose.”

More information about the trial can be found at www.clinicaltrials.gov.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumors including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. ENMD-2076 is currently in Phase 2 clinical trials in multiple indications, including triple-negative breast cancer, soft tissue sarcoma, ovarian clear cell carcinomas and fibrolamellar carcinoma. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma.  ENMD-2076 has received orphan drug designation from the European Medicines Agency Committee for Orphan Medicinal Products for the treatment of hepatocellular carcinoma, including fibrolamellar carcinoma.

About CASI Pharmaceuticals, Inc.

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China. CASI’s product pipeline includes exclusive rights to MARQIBO® (vinCRIStine sulfate LIPOSOME injection), EVOMELA® (melphalan) for Injection and ZEVALIN® (ibritumomab tiuxetan) for the greater China market (including Taiwan, Hong Kong and Macau). CASI’s development pipeline also includes its proprietary drug candidate ENMD-2076, a selective angiogenic kinase inhibitor currently in multiple Phase 2 oncology studies, and 2ME2 (2-methoxyestradial) currently under reformulation development. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals, including, without limitation, with respect to the closing of the private placement offering and the anticipated use of the net proceeds.  Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.  Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that the remaining closing or closings of the private placement offering does not occur, that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, including as a result of the closing of the private placement offering; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

MARQIBO®, EVOMELA® and ZEVALIN® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

COMPANY CONTACT:CASI Pharmaceuticals, Inc.

240.864.2643

ir@casipharmaceuticals.com

INVESTOR CONTACT:Torrey Hills Capital

Jim Macdonald

858.456.7300

jmacdonald@torreyhillscapital.com

Tuesday, August 16th, 2016 Uncategorized Comments Off on $CASI Update #Phase2 #Trial Of #ENMD2076 in #Cancer

$STEM and #MicrobotMedical Announce #StrategicMerger

Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions

NEWARK, Calif. and YOKNEAM, Israel, Aug. 16, 2016  — StemCells, Inc. (NASDAQ:STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel (“Microbot”), today announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions.

This transaction concludes an extensive search for strategic alternatives conducted by StemCells since we failed to see robust clinical results in our Phase II clinical study of human neural stem cells in chronic spinal cord injury,” said Ian Massey, the CEO of StemCells, Inc.  “We believe both our investors and the market at large will see the potential of Microbot’s robotics platform, specifically its catheter and shunt technologies, and will appreciate Microbot’s overall business opportunities and potential.”

Harel Gadot, the CEO & Chairman of Microbot added, “We are pleased that this transaction will give us a presence in the U.S. capital markets, and we are very excited to continue advancing the development of our proprietary technologies that we believe have the potential to improve the lives of many patients globally. We thank StemCells for its efforts and contributions to improving human health over the years.”

The board of directors of each company has unanimously approved the terms of the merger agreement and has recommended that its shareholders approve the transaction. Completion of the merger is subject to approval of the StemCells and Microbot shareholders and certain regulatory approvals and customary conditions. In addition, in order to satisfy certain closing conditions for the merger, StemCells will be negotiating reductions in outstanding balances with its creditors.

Ropes & Gray LLP acted as legal advisor to StemCells and Ruskin Moscou Faltischek, P.C. and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as legal advisor to Microbot.  Additional information about the proposed transaction can be found in the Form 8‑K filed by StemCells on August 15, 2016.

CAUTIONARY INFORMATION ABOUT FORWARD-LOOKING STATEMENTS

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the “Company”), the prospect for development of Microbot’s medical devices, the possibility of a merger transaction between the companies, and possible benefits from such a merger for the companies and their respective stakeholders. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties about the parties’ ability to complete the merger; uncertainties concerning the sufficiency of the Company’s remaining funds to continue operations; uncertainties regarding the Company’s plans to increase its authorized share capital; uncertainties regarding the validity and enforceability of the Company’s patents and Microbot’s patents; uncertainties as to whether either company will become profitable; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016.

IMPORTANT INFORMATION FOR INVESTORS AND SHAREHOLDERS

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval.

A definitive proxy statement and a proxy card will be filed with the SEC and will be mailed to the Company’s stockholders seeking any required stockholder approvals in connection with the proposed transactions. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders may obtain, free of charge, copies of the definitive proxy statement and any other documents filed by StemCells with the SEC in connection with the proposed transactions at the SEC’s website (http://www.sec.gov), at StemCells’ website, or by directing written request to: StemCells, Inc. 39899 Balentine Drive, Suite 200, Newark, CA 94560, Attention: Kenneth Stratton, Esq.

The Company and its directors and executive officers and Microbot and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger will be included in the proxy statement referred to above. Additional information regarding the directors and executive officers of the Company is also included in the Company’s Definitive Proxy Statement on Schedule 14A relating to the 2016 Annual Meeting of Stockholders, which was filed with the SEC on April 8, 2016. This document is available free of charge at the SEC web site (www.sec.gov), at the Company’s website, or by directing a written request to the Company as described above

 

CONTACT:

Ken Stratton
StemCells, Inc.
(650) 670-2282
Tuesday, August 16th, 2016 Uncategorized Comments Off on $STEM and #MicrobotMedical Announce #StrategicMerger
Top Small Cap Market News